data_2lzr_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lzr _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.08 0 CA-C-O 120.715 0.293 . . . . 0.0 110.415 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -62.55 -43.6 98.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.083 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.471 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -62.32 -44.46 99.2 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.68 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.768 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 45.1 t -58.9 -45.21 91.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.428 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.4 t -62.62 -43.43 98.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.218 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.0 mt -63.29 -48.16 79.29 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.989 -178.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.1 mt -63.96 -41.69 97.5 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.504 -0.479 . . . . 0.0 110.767 -178.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -87.93 -12.77 43.66 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.58 161.5 0.03 OUTLIER Glycine 0 CA--C 1.54 1.636 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -70.0 -25.13 27.78 Favored 'Trans proline' 0 N--CA 1.502 1.994 0 C-N-CA 121.5 1.467 . . . . 0.0 114.572 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -66.72 -50.7 61.95 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.342 -0.543 . . . . 0.0 112.416 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -67.3 -44.97 77.89 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.534 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt . . . . . 0 C--N 1.324 -0.525 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.773 -179.128 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.764 0.316 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 52.9 t -63.71 -44.09 98.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.088 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.445 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 78.9 mt -61.53 -44.54 98.78 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.732 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.5 t -57.7 -43.77 84.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 C-N-CA 120.29 -0.564 . . . . 0.0 110.344 -179.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.8 t -63.86 -43.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.186 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 36.0 mt -62.73 -49.13 76.25 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.811 -178.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 36.3 mt -62.73 -42.33 99.61 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.326 -0.55 . . . . 0.0 110.626 -178.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -87.23 -14.1 42.01 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 121.062 -0.255 . . . . 0.0 111.676 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.54 161.96 0.04 OUTLIER Glycine 0 CA--C 1.543 1.807 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -68.87 -20.9 38.58 Favored 'Trans proline' 0 N--CA 1.504 2.141 0 C-N-CA 121.58 1.52 . . . . 0.0 114.772 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -69.21 -50.86 43.46 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -67.66 -47.09 70.52 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.355 -0.538 . . . . 0.0 110.477 -179.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt . . . . . 0 C--N 1.324 -0.531 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.702 -179.174 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.852 0.358 . . . . 0.0 110.389 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.6 t -60.75 -43.01 94.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.03 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -59.8 -43.37 91.65 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.592 0 C-N-CA 120.167 -0.613 . . . . 0.0 110.698 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.0 t -57.0 -43.84 81.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.386 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.6 t -61.99 -44.07 98.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.194 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.1 mt -62.76 -48.0 81.06 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.757 -178.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.448 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 29.1 mt -63.88 -41.69 97.68 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.613 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' A' ' 21' ' ' GLY . 40.5 m-85 -86.81 -13.07 46.15 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 111.57 0.211 . . . . 0.0 111.57 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.13 160.28 0.02 OUTLIER Glycine 0 CA--C 1.54 1.631 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.76 -16.27 33.36 Favored 'Trans proline' 0 N--CA 1.502 2.029 0 C-N-CA 121.502 1.468 . . . . 0.0 114.507 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.0 ttpt -67.48 -52.72 35.97 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -68.56 -47.54 66.58 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.533 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--N 1.325 -0.497 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.581 -179.185 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.761 0.315 . . . . 0.0 110.351 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.8 t -62.51 -44.14 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.026 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.455 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.7 mt -61.58 -44.77 99.19 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.75 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.5 t -58.79 -44.44 90.31 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.528 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.2 t -63.15 -43.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.229 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 34.9 mt -62.95 -48.23 79.79 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.944 -178.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.455 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -64.11 -40.55 96.46 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.87 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -88.69 -14.65 36.81 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 111.637 0.236 . . . . 0.0 111.637 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 60.76 160.54 0.09 OUTLIER Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -70.28 -27.66 23.7 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.461 1.441 . . . . 0.0 114.666 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -65.84 -49.78 66.95 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -67.12 -44.99 78.52 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.434 -179.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.1 tt . . . . . 0 C--N 1.324 -0.516 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.78 -179.174 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.14 0 CA-C-O 120.842 0.354 . . . . 0.0 110.307 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 40.4 t -60.83 -43.1 94.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.944 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.441 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.4 mt -60.67 -44.04 96.2 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.533 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.751 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.8 t -57.67 -44.32 85.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.389 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.0 t -62.71 -43.81 98.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.238 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.3 mt -62.69 -48.12 80.67 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.729 -178.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.441 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -63.6 -42.05 98.27 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.467 -0.493 . . . . 0.0 110.757 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.9 m-85 -86.77 -12.07 49.18 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.509 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.18 160.21 0.01 OUTLIER Glycine 0 CA--C 1.543 1.806 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -72.82 -12.73 26.55 Favored 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 121.434 1.423 . . . . 0.0 114.544 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.52 -55.13 12.73 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 120.301 -0.559 . . . . 0.0 112.338 -179.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -68.82 -46.9 67.42 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.175 0.512 . . . . 0.0 110.584 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 8.8 tt . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.68 -178.767 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.797 0.332 . . . . 0.0 110.458 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -62.39 -45.54 98.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.202 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.459 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 74.3 mt -61.79 -45.46 98.65 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.644 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.806 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.1 t -58.48 -44.22 88.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.49 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.529 ' O ' ' N ' ' A' ' 21' ' ' GLY . 75.5 t -63.72 -43.33 97.99 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.202 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.7 mt -63.13 -48.31 79.07 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.922 -178.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.459 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.8 mt -64.35 -41.89 96.51 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.757 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 21' ' ' GLY . 45.6 m-85 -88.35 -12.01 44.61 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.13 162.23 0.02 OUTLIER Glycine 0 CA--C 1.542 1.748 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -69.46 -25.52 29.89 Favored 'Trans proline' 0 N--CA 1.503 2.03 0 C-N-CA 121.505 1.47 . . . . 0.0 114.74 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.67 -50.59 62.41 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 120.324 -0.551 . . . . 0.0 112.366 -178.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 31.8 mmtp -67.07 -45.3 77.73 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.387 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.4 tt . . . . . 0 C--N 1.324 -0.507 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.732 -179.232 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.784 0.326 . . . . 0.0 110.546 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.4 t -64.03 -43.27 97.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.071 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.447 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 77.8 mt -61.04 -43.93 97.2 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.744 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.39 -44.31 84.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.377 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.1 t -63.44 -43.56 98.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.119 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.9 mt -62.83 -48.63 78.25 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.75 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.1 mt -63.9 -42.78 97.36 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.666 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.416 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.1 m-85 -86.19 -13.69 46.22 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.622 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 55.87 163.2 0.02 OUTLIER Glycine 0 CA--C 1.541 1.687 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -70.14 -19.62 34.07 Favored 'Trans proline' 0 N--CA 1.501 1.936 0 C-N-CA 121.584 1.523 . . . . 0.0 114.583 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -67.8 -52.23 39.46 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 120.292 -0.563 . . . . 0.0 112.283 -179.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -67.58 -44.1 78.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.209 0.528 . . . . 0.0 110.398 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.6 tt . . . . . 0 C--N 1.327 -0.402 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.668 -179.04 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.164 0 CA-C-O 120.745 0.307 . . . . 0.0 110.599 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.8 t -63.52 -45.32 98.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.784 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.451 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 79.9 mt -61.92 -44.62 99.13 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 C-N-CA 120.172 -0.611 . . . . 0.0 110.854 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 69.0 t -59.19 -44.59 92.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.401 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.6 t -63.44 -44.07 98.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.192 -179.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 34.2 mt -62.39 -48.57 79.14 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.576 -0.45 . . . . 0.0 112.156 -178.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.451 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 47.9 mt -63.91 -40.79 97.3 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.965 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -90.06 -13.73 35.29 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 121.202 -0.199 . . . . 0.0 111.51 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.33 163.36 0.04 OUTLIER Glycine 0 CA--C 1.532 1.124 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -68.79 -25.19 33.66 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.107 1.204 . . . . 0.0 114.443 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 tptp -67.19 -50.34 61.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.038 -0.665 . . . . 0.0 112.599 -178.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.6 mmtt -66.98 -45.44 77.65 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.343 -178.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 10.0 tt . . . . . 0 C--N 1.324 -0.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.415 -179.1 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.891 0.377 . . . . 0.0 110.432 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.76 -42.94 96.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.079 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.435 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.1 mt -60.77 -43.93 96.33 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.568 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.689 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 44.9 t -57.88 -43.98 85.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.387 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.496 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.6 t -63.18 -43.44 98.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.086 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 34.0 mt -62.82 -48.54 78.65 Favored 'General case' 0 C--N 1.33 -0.26 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.751 -178.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.435 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.3 mt -64.01 -42.06 97.26 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.667 -179.074 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' A' ' 21' ' ' GLY . 38.9 m-85 -85.47 -12.99 50.5 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 121.143 -0.223 . . . . 0.0 111.595 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.62 159.12 0.01 OUTLIER Glycine 0 CA--C 1.54 1.641 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -70.24 -22.5 29.78 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.465 1.444 . . . . 0.0 114.625 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -67.73 -52.33 38.79 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 120.449 -0.501 . . . . 0.0 112.256 -179.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 42.5 tttp -66.29 -44.61 83.03 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 120.447 -0.501 . . . . 0.0 110.443 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt . . . . . 0 C--N 1.324 -0.538 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.653 -179.11 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.121 0 CA-C-O 120.814 0.34 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.0 t -62.47 -44.17 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.067 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.449 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.6 mt -61.87 -44.96 99.59 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.612 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.936 -179.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 52.1 t -58.84 -44.22 90.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.473 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' GLY . 73.5 t -63.63 -43.38 98.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.71 -0.396 . . . . 0.0 111.249 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 37.2 mt -63.16 -48.47 78.3 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.98 -178.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 42.3 mt -64.19 -41.02 97.26 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.872 -179.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 21' ' ' GLY . 44.7 m-85 -88.89 -12.28 42.21 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 111.609 0.226 . . . . 0.0 111.609 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.42 161.26 0.02 OUTLIER Glycine 0 CA--C 1.54 1.63 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.25 -24.96 26.85 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 121.466 1.444 . . . . 0.0 114.718 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.76 -51.18 58.83 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 120.398 -0.521 . . . . 0.0 112.371 -178.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -67.28 -45.02 77.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt . . . . . 0 C--N 1.324 -0.506 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.716 -178.948 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.27 -36.64 93.47 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 153.47 19.72 0.05 OUTLIER Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 74.4 mt -64.65 -25.05 36.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.055 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.2 t -65.06 130.4 43.21 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.107 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.3 tt -65.15 -40.67 89.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.1 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -58.84 -31.68 68.73 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.161 179.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -64.23 -38.38 90.83 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.252 -0.579 . . . . 0.0 109.74 179.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 69.2 mt -70.62 -36.26 73.39 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.184 -0.607 . . . . 0.0 110.587 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -62.43 -48.27 80.43 Favored 'General case' 0 C--O 1.23 0.067 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -178.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.422 ' CG2' ' N ' ' A' ' 12' ' ' ILE . 20.0 tt -67.05 -42.17 88.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.024 -178.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.422 ' N ' ' CG2' ' A' ' 11' ' ' ILE . 95.1 mt -63.52 -43.48 98.34 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.134 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.24 179.519 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.29 -39.2 82.21 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.415 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -62.55 -43.6 98.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.083 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.471 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -62.32 -44.46 99.2 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.68 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.768 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 45.1 t -58.9 -45.21 91.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.428 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.4 t -62.62 -43.43 98.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.218 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.0 mt -63.29 -48.16 79.29 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.989 -178.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.1 mt -63.96 -41.69 97.5 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.504 -0.479 . . . . 0.0 110.767 -178.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -87.93 -12.77 43.66 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.58 161.5 0.03 OUTLIER Glycine 0 CA--C 1.54 1.636 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -70.0 -25.13 27.78 Favored 'Trans proline' 0 N--CA 1.502 1.994 0 C-N-CA 121.5 1.467 . . . . 0.0 114.572 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -66.72 -50.7 61.95 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.342 -0.543 . . . . 0.0 112.416 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -67.3 -44.97 77.89 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.534 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt -61.56 -29.85 70.28 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.773 -179.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.98 -51.06 48.48 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.0 p -66.13 -41.36 90.57 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.876 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 92.7 mt -64.61 -46.91 91.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.703 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.77 -51.05 56.92 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.6 t -60.28 -42.03 94.58 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.981 -0.288 . . . . 0.0 110.734 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -62.36 -45.36 93.53 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.014 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 74.8 mt -80.51 -20.25 44.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.559 179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -82.93 1.15 89.08 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -67.13 -35.73 80.37 Favored 'General case' 0 C--O 1.231 0.115 0 O-C-N 122.566 -0.373 . . . . 0.0 110.903 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.9 p -67.72 -37.97 82.95 Favored 'General case' 0 C--O 1.224 -0.271 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.526 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 88.8 mt -62.48 -41.16 90.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.037 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -56.66 -38.13 71.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.025 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.95 -38.19 92.67 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -61.99 -45.59 92.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.878 0.371 . . . . 0.0 110.037 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.0 tttp -64.53 -46.08 84.42 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.525 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.457 ' O ' ' OG ' ' A' ' 44' ' ' SER . 65.9 tttm -59.38 -50.41 74.05 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 120.608 -0.437 . . . . 0.0 110.607 -179.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.96 -43.59 77.64 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.958 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 37.3 mtm -75.75 0.88 16.34 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 120.994 -0.283 . . . . 0.0 110.593 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 41' ' ' LYS . 59.2 p -67.91 -38.02 82.43 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.815 0.341 . . . . 0.0 110.58 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -63.11 -41.74 99.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.367 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.525 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 38.8 t70 -78.21 177.35 8.46 Favored 'General case' 0 C--O 1.232 0.146 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.628 ' OE2' ' N ' ' A' ' 47' ' ' GLU . 0.8 OUTLIER -153.62 80.91 5.0 Favored Pre-proline 0 CA--C 1.536 0.42 0 C-N-CA 120.803 -0.359 . . . . 0.0 111.6 179.958 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -53.23 -36.9 79.52 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 120.808 1.005 . . . . 0.0 111.718 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 20.9 ptmt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.089 -179.843 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.53 62.98 3.76 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -155.53 147.56 16.58 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.868 -0.893 . . . . 0.0 110.868 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 78.5 mt -107.21 123.77 62.62 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.079 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.5 t -74.58 128.63 36.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.994 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.3 tt -65.96 -40.42 87.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.938 0.399 . . . . 0.0 110.215 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 3.6 m95 -60.81 -30.02 69.82 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.294 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 25.3 mm-40 -63.16 -34.76 78.33 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.213 -0.595 . . . . 0.0 109.788 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 66.3 mt -71.62 -35.06 70.33 Favored 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.074 -0.65 . . . . 0.0 110.594 179.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 mt -62.18 -46.29 89.62 Favored 'General case' 0 CA--C 1.526 0.046 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -178.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.46 ' CG2' ' N ' ' A' ' 12' ' ' ILE . 16.9 tt -64.82 -42.97 96.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.994 -178.565 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.46 ' N ' ' CG2' ' A' ' 11' ' ' ILE . 81.2 mt -64.73 -42.91 96.3 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.385 179.681 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.9 -41.1 97.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.764 0.316 . . . . 0.0 110.424 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 52.9 t -63.71 -44.09 98.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.088 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.445 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 78.9 mt -61.53 -44.54 98.78 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.732 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.5 t -57.7 -43.77 84.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 C-N-CA 120.29 -0.564 . . . . 0.0 110.344 -179.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.8 t -63.86 -43.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.186 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 36.0 mt -62.73 -49.13 76.25 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.811 -178.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 36.3 mt -62.73 -42.33 99.61 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.326 -0.55 . . . . 0.0 110.626 -178.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -87.23 -14.1 42.01 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 121.062 -0.255 . . . . 0.0 111.676 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.54 161.96 0.04 OUTLIER Glycine 0 CA--C 1.543 1.807 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -68.87 -20.9 38.58 Favored 'Trans proline' 0 N--CA 1.504 2.141 0 C-N-CA 121.58 1.52 . . . . 0.0 114.772 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -69.21 -50.86 43.46 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -67.66 -47.09 70.52 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.355 -0.538 . . . . 0.0 110.477 -179.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt -61.21 -27.8 68.69 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.702 -179.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.12 -50.81 55.41 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 46.2 t -65.53 -41.08 93.5 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.713 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.407 HD12 HG22 ' A' ' 28' ' ' ILE . 97.5 mt -63.88 -47.07 92.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.187 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.849 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.38 -51.22 56.35 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 72.5 p -59.86 -42.03 92.78 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 121.009 -0.276 . . . . 0.0 110.828 -179.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -61.27 -45.75 93.2 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.093 179.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.9 mt -80.34 -19.84 45.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.707 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -74.84 -1.52 62.53 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 -179.508 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.25 -34.55 78.36 Favored 'General case' 0 C--N 1.332 -0.175 0 C-N-CA 120.769 -0.373 . . . . 0.0 110.522 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.7 m -65.37 -34.01 77.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.022 0.439 . . . . 0.0 110.563 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.6 mt -61.84 -40.78 88.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.949 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -56.94 -41.65 78.62 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.076 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.21 -37.67 93.16 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -62.3 -45.78 91.72 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -63.06 -46.26 88.31 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.435 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -58.91 -51.29 70.69 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 120.421 -0.512 . . . . 0.0 110.561 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.45 -44.27 80.32 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.136 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 16.8 mtm -77.06 12.5 1.39 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 121.133 -0.227 . . . . 0.0 110.622 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 60.5 p -133.01 4.93 3.83 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 120.888 0.375 . . . . 0.0 110.771 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -127.95 -75.65 0.57 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.41 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.533 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 37.7 t70 -163.15 179.25 7.6 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.071 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.533 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 7.6 mp0 -141.33 81.17 15.8 Favored Pre-proline 0 CA--C 1.54 0.577 0 C-N-CA 120.659 -0.417 . . . . 0.0 111.38 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -52.9 -38.21 78.63 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 121.031 1.154 . . . . 0.0 111.828 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 C--N 1.332 -0.158 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.225 -179.669 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.24 13.11 81.35 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 82.72 2.99 90.69 Favored Glycine 0 CA--C 1.521 0.409 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 93.4 mt -103.89 114.03 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-O 120.746 0.308 . . . . 0.0 110.342 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.4 t -77.11 160.79 28.77 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.935 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.3 tt -64.99 -39.05 84.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.931 0.396 . . . . 0.0 110.226 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.4 m95 -58.84 -29.09 66.67 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.038 179.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -62.52 -30.5 71.33 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.181 -0.608 . . . . 0.0 109.461 179.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.7 mt -71.64 -37.86 70.8 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 120.072 -0.651 . . . . 0.0 110.627 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.4 mt -62.26 -47.47 84.23 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 111.959 0.355 . . . . 0.0 111.959 -178.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.426 ' CG2' ' N ' ' A' ' 12' ' ' ILE . 20.2 tt -65.91 -42.56 92.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.035 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.426 ' N ' ' CG2' ' A' ' 11' ' ' ILE . 92.6 mt -63.17 -42.85 98.06 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.151 0 C-N-CA 120.751 -0.38 . . . . 0.0 110.232 179.282 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.81 -38.17 84.5 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.852 0.358 . . . . 0.0 110.389 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.6 t -60.75 -43.01 94.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.03 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -59.8 -43.37 91.65 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.592 0 C-N-CA 120.167 -0.613 . . . . 0.0 110.698 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.0 t -57.0 -43.84 81.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.386 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.6 t -61.99 -44.07 98.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.194 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.1 mt -62.76 -48.0 81.06 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.757 -178.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.448 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 29.1 mt -63.88 -41.69 97.68 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.613 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' A' ' 21' ' ' GLY . 40.5 m-85 -86.81 -13.07 46.15 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 111.57 0.211 . . . . 0.0 111.57 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.13 160.28 0.02 OUTLIER Glycine 0 CA--C 1.54 1.631 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.76 -16.27 33.36 Favored 'Trans proline' 0 N--CA 1.502 2.029 0 C-N-CA 121.502 1.468 . . . . 0.0 114.507 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.0 ttpt -67.48 -52.72 35.97 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -68.56 -47.54 66.58 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.533 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.87 -26.69 68.9 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.581 -179.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -66.22 -51.13 46.46 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -66.98 -41.74 86.28 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.791 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.02 -47.96 88.08 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.148 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.725 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.02 -50.87 59.78 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.054 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.2 m -60.64 -39.94 90.11 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 121.171 -0.211 . . . . 0.0 110.893 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -63.49 -45.31 91.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.89 0.376 . . . . 0.0 110.103 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.2 mt -79.11 -14.85 58.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.59 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -82.93 3.82 82.52 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -67.4 -37.65 83.45 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.795 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 78.1 p -68.82 -38.81 80.15 Favored 'General case' 0 C--O 1.224 -0.256 0 CA-C-O 121.049 0.452 . . . . 0.0 110.703 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.2 mt -63.4 -41.61 93.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.018 179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -56.58 -42.62 78.96 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.14 -178.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.96 -41.32 97.41 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.112 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -61.76 -45.75 92.56 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -64.25 -46.41 83.87 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.513 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -59.82 -50.53 73.43 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 120.599 -0.44 . . . . 0.0 110.713 -179.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.13 -42.06 76.3 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.079 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 25.1 mtm -76.53 13.6 0.95 Allowed 'General case' 0 CA--C 1.536 0.442 0 O-C-N 122.238 -0.289 . . . . 0.0 110.74 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 35.2 t -76.26 -3.95 39.33 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.686 0.279 . . . . 0.0 110.459 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -62.4 -39.9 94.75 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.458 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.434 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 45.9 t0 58.95 177.06 0.07 Allowed 'General case' 0 C--O 1.231 0.123 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.434 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 35.4 mt-10 -155.98 147.9 17.29 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.816 179.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -64.93 -23.98 61.19 Favored 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 120.99 1.127 . . . . 0.0 111.9 179.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 62.8 mttp . . . . . 0 C--N 1.332 -0.192 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.387 -179.658 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.2 -38.55 96.68 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -169.55 168.96 41.72 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 96.1 mt -85.37 126.59 40.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.9 t -84.23 128.33 34.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.198 -0.455 . . . . 0.0 109.862 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.5 tt -64.58 -40.52 89.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.168 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -58.51 -30.9 67.41 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.01 179.354 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -65.23 -37.64 87.89 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 179.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 90.4 mt -70.81 -36.96 73.2 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.122 -0.631 . . . . 0.0 110.17 178.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.8 tt -62.54 -48.42 79.6 Favored 'General case' 0 CA--C 1.527 0.092 0 N-CA-C 112.06 0.393 . . . . 0.0 112.06 -178.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.429 ' CG2' ' N ' ' A' ' 12' ' ' ILE . 19.5 tt -66.06 -42.62 91.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.052 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.429 ' N ' ' CG2' ' A' ' 11' ' ' ILE . 95.2 mt -63.71 -42.92 97.62 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.403 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.37 -38.62 84.48 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.351 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.8 t -62.51 -44.14 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.026 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.455 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.7 mt -61.58 -44.77 99.19 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.75 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.5 t -58.79 -44.44 90.31 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.528 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.2 t -63.15 -43.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.229 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 34.9 mt -62.95 -48.23 79.79 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.944 -178.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.455 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -64.11 -40.55 96.46 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.87 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -88.69 -14.65 36.81 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 111.637 0.236 . . . . 0.0 111.637 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 60.76 160.54 0.09 OUTLIER Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -70.28 -27.66 23.7 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.461 1.441 . . . . 0.0 114.666 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -65.84 -49.78 66.95 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -67.12 -44.99 78.52 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.434 -179.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.1 tt -61.37 -29.56 69.98 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.78 -179.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.46 -50.99 52.34 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 39.1 m -64.25 -40.55 96.24 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.852 179.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.6 mt -64.49 -47.61 88.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.731 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.447 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -61.83 -50.97 60.57 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 120.395 -0.907 . . . . 0.0 110.875 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 76.1 p -60.57 -39.81 89.37 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 121.054 -0.259 . . . . 0.0 110.848 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -62.24 -45.6 92.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.916 0.388 . . . . 0.0 110.155 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.4 mt -80.2 -18.19 50.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.743 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -77.49 1.31 66.51 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.38 -36.27 82.43 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.886 0.374 . . . . 0.0 110.921 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 36.5 t -66.38 -36.91 84.06 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.514 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 86.0 mt -61.73 -40.76 87.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.206 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -56.28 -38.87 71.78 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.036 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.34 -36.48 91.71 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -62.78 -47.01 85.34 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.019 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -63.39 -46.58 85.77 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.525 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -58.78 -50.77 72.72 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.713 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.23 -44.85 79.97 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 119.681 -0.808 . . . . 0.0 111.196 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.429 ' O ' ' O ' ' A' ' 44' ' ' SER . 34.1 ttm -77.57 13.4 1.28 Allowed 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 121.082 -0.247 . . . . 0.0 110.841 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 43' ' ' MET . 10.6 t 58.25 151.87 0.01 OUTLIER 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.678 0.275 . . . . 0.0 110.682 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -85.65 -89.21 0.11 Allowed 'General case' 0 CA--C 1.524 -0.028 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.422 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -97.57 48.96 1.03 Allowed 'General case' 0 C--N 1.339 0.136 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.252 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.526 ' OE2' ' NZ ' ' A' ' 49' ' ' LYS . 39.0 tt0 -165.3 90.15 0.94 Allowed Pre-proline 0 CA--C 1.536 0.438 0 C-N-CA 120.434 -0.507 . . . . 0.0 111.091 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -59.91 145.74 97.56 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 120.881 1.054 . . . . 0.0 111.736 179.318 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.526 ' NZ ' ' OE2' ' A' ' 47' ' ' GLU . 69.7 mmtt . . . . . 0 N--CA 1.463 0.21 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.143 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' FME . . . . . 0.564 ' N ' ' SD ' ' A' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.77 -39.09 97.1 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -83.58 -163.92 35.75 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.41 HD12 HG21 ' A' ' 4' ' ' ILE . 92.0 mt -87.07 114.96 27.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 121.004 0.43 . . . . 0.0 110.046 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.4 t -70.6 150.07 46.43 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.095 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.8 tt -64.53 -37.81 81.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.018 0.437 . . . . 0.0 110.102 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.1 m95 -58.37 -29.53 66.07 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.866 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 -62.07 -31.71 72.17 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.009 -0.676 . . . . 0.0 109.634 179.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.6 mt -70.87 -37.37 73.06 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.66 179.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 mt -62.09 -46.51 88.75 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 14.6 tt -67.18 -42.42 88.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.282 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 82.6 mt -62.84 -43.33 98.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.275 179.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.82 -38.32 81.68 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.842 0.354 . . . . 0.0 110.307 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 40.4 t -60.83 -43.1 94.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.944 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.441 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.4 mt -60.67 -44.04 96.2 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.533 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.751 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.8 t -57.67 -44.32 85.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.389 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.0 t -62.71 -43.81 98.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.238 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.3 mt -62.69 -48.12 80.67 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.729 -178.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.441 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -63.6 -42.05 98.27 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.467 -0.493 . . . . 0.0 110.757 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.9 m-85 -86.77 -12.07 49.18 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.509 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.18 160.21 0.01 OUTLIER Glycine 0 CA--C 1.543 1.806 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -72.82 -12.73 26.55 Favored 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 121.434 1.423 . . . . 0.0 114.544 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.52 -55.13 12.73 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 120.301 -0.559 . . . . 0.0 112.338 -179.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -68.82 -46.9 67.42 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.175 0.512 . . . . 0.0 110.584 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 8.8 tt -63.49 -23.54 67.44 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.68 -178.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.59 -51.57 35.54 Favored Glycine 0 C--N 1.333 0.381 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 9.5 t -65.69 -43.02 90.48 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.037 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.7 mt -64.34 -47.68 88.57 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.976 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -64.44 -50.94 56.52 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.009 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 13.1 t -59.69 -41.91 91.78 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 121.111 -0.236 . . . . 0.0 110.66 -179.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -63.44 -46.18 87.48 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 120.691 -0.403 . . . . 0.0 110.381 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 69.0 mt -79.51 -20.98 45.9 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.669 179.322 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -82.17 0.65 88.53 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 111.558 -0.617 . . . . 0.0 111.558 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.72 -39.31 87.95 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.672 -179.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.5 m -69.54 -43.96 71.9 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.007 0.432 . . . . 0.0 110.793 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.5 mt -63.1 -41.36 92.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.012 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 66.6 tttm -56.44 -42.89 78.85 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.822 -0.627 . . . . 0.0 111.014 -178.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.22 -44.81 96.51 Favored Glycine 0 CA--C 1.522 0.489 0 C-N-CA 120.341 -0.933 . . . . 0.0 110.773 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -63.39 -44.88 93.42 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -60.04 -46.0 90.97 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.472 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -65.39 -53.29 45.39 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.971 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -59.8 -31.58 69.83 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 119.756 -0.778 . . . . 0.0 111.184 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.513 ' C ' ' H ' ' A' ' 45' ' ' ASP . 32.1 mmm -75.28 13.2 0.76 Allowed 'General case' 0 N--CA 1.453 -0.297 0 O-C-N 122.387 -0.196 . . . . 0.0 110.723 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 12.6 t 46.25 14.14 0.02 OUTLIER 'General case' 0 C--O 1.231 0.111 0 C-N-CA 120.962 -0.295 . . . . 0.0 110.724 179.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 43' ' ' MET . 35.6 t70 -60.62 -43.24 97.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.45 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.529 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 37.0 t70 -51.91 178.87 0.01 OUTLIER 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.04 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.529 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 3.6 tp10 75.07 111.55 0.03 OUTLIER Pre-proline 0 CA--C 1.544 0.715 0 C-N-CA 120.918 -0.313 . . . . 0.0 110.874 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -72.45 155.54 55.17 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 120.874 1.049 . . . . 0.0 111.79 179.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 62.6 pttt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.254 179.239 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.56 -174.12 43.65 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.934 -0.867 . . . . 0.0 110.934 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 153.31 -8.81 0.49 Allowed Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 97.9 mt -63.16 -44.04 99.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.017 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 41.4 t -71.57 131.75 43.69 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.909 179.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 tt -66.0 -39.77 85.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.336 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.2 m95 -58.72 -28.42 65.82 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.182 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 68.9 tp60 -62.82 -31.36 72.34 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.259 -0.576 . . . . 0.0 109.717 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.7 mt -70.77 -38.34 73.43 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.163 -0.615 . . . . 0.0 110.414 178.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.2 mt -62.34 -48.18 80.96 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 111.933 0.346 . . . . 0.0 111.933 -178.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.433 ' CG2' ' N ' ' A' ' 12' ' ' ILE . 20.0 tt -65.52 -42.95 94.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.158 -178.796 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.433 ' N ' ' CG2' ' A' ' 11' ' ' ILE . 77.8 mt -64.54 -43.4 96.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.518 179.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.69 -42.23 99.53 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.797 0.332 . . . . 0.0 110.458 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -62.39 -45.54 98.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.202 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.459 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 74.3 mt -61.79 -45.46 98.65 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.644 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.806 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.1 t -58.48 -44.22 88.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.49 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.529 ' O ' ' N ' ' A' ' 21' ' ' GLY . 75.5 t -63.72 -43.33 97.99 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.202 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.7 mt -63.13 -48.31 79.07 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.922 -178.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.459 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.8 mt -64.35 -41.89 96.51 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.757 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 21' ' ' GLY . 45.6 m-85 -88.35 -12.01 44.61 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.13 162.23 0.02 OUTLIER Glycine 0 CA--C 1.542 1.748 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -69.46 -25.52 29.89 Favored 'Trans proline' 0 N--CA 1.503 2.03 0 C-N-CA 121.505 1.47 . . . . 0.0 114.74 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.67 -50.59 62.41 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 120.324 -0.551 . . . . 0.0 112.366 -178.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 31.8 mmtp -67.07 -45.3 77.73 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.387 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.4 tt -61.46 -29.63 70.08 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.732 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.87 -50.98 49.82 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 28.2 m -66.49 -40.92 89.56 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.897 179.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.5 mt -64.72 -47.53 88.34 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.687 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.23 -51.21 56.72 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.1 m -60.59 -40.4 91.61 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.883 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -63.22 -45.25 92.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.848 0.356 . . . . 0.0 110.161 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.2 mt -79.1 -14.9 58.86 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.601 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -82.3 3.67 80.47 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -68.7 -39.2 80.6 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.887 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 39.0 t -65.6 -43.0 90.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.905 0.383 . . . . 0.0 110.584 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 87.6 mt -62.55 -41.38 91.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.751 -0.658 . . . . 0.0 109.987 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -56.37 -39.46 72.97 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.035 -178.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.02 -41.0 88.46 Favored Glycine 0 CA--C 1.52 0.389 0 C-N-CA 120.547 -0.835 . . . . 0.0 111.088 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -62.0 -47.13 86.15 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -63.91 -46.47 84.65 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.314 -0.555 . . . . 0.0 110.798 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -59.74 -50.31 74.31 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.759 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.69 -44.46 77.38 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.166 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 2.8 tpp -77.01 12.84 1.23 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 121.021 -0.271 . . . . 0.0 110.865 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 13.2 t -82.39 50.0 1.54 Allowed 'General case' 0 C--O 1.232 0.184 0 CA-C-O 120.692 0.282 . . . . 0.0 110.302 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -62.51 -40.97 98.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.566 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.514 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 38.9 t70 -150.1 178.83 8.59 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.921 -0.312 . . . . 0.0 110.177 179.487 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.514 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 26.2 tt0 -162.83 87.67 1.34 Allowed Pre-proline 0 CA--C 1.537 0.463 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.36 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -76.5 158.37 36.3 Favored 'Trans proline' 0 N--CA 1.492 1.432 0 C-N-CA 121.215 1.277 . . . . 0.0 111.703 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 98.9 mttt . . . . . 0 C--N 1.333 -0.133 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.011 179.517 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' FME . . . . . 0.541 ' SD ' ' CN ' ' A' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -87.1 120.34 5.47 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -94.41 9.99 71.45 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 97.1 mt -63.19 -43.73 98.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.707 -0.397 . . . . 0.0 109.94 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.1 t -66.88 134.16 51.5 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.208 179.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.2 tt -65.34 -41.2 90.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.018 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.1 m95 -59.92 -31.32 69.72 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.178 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 41.7 mm-40 -64.99 -38.48 91.1 Favored 'General case' 0 C--O 1.22 -0.455 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.659 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 60.8 mt -71.68 -34.57 69.8 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.438 178.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -61.86 -47.13 86.4 Favored 'General case' 0 C--O 1.233 0.237 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 -177.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.444 ' CG2' ' N ' ' A' ' 12' ' ' ILE . 17.6 tt -65.21 -42.04 93.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.21 -178.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.444 ' N ' ' CG2' ' A' ' 11' ' ' ILE . 84.9 mt -64.15 -42.89 96.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.461 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.2 -40.7 94.93 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.784 0.326 . . . . 0.0 110.546 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.4 t -64.03 -43.27 97.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.071 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.447 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 77.8 mt -61.04 -43.93 97.2 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.744 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.39 -44.31 84.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.377 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.1 t -63.44 -43.56 98.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.119 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.9 mt -62.83 -48.63 78.25 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.75 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.447 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.1 mt -63.9 -42.78 97.36 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.666 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.416 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.1 m-85 -86.19 -13.69 46.22 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.622 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 55.87 163.2 0.02 OUTLIER Glycine 0 CA--C 1.541 1.687 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -70.14 -19.62 34.07 Favored 'Trans proline' 0 N--CA 1.501 1.936 0 C-N-CA 121.584 1.523 . . . . 0.0 114.583 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -67.8 -52.23 39.46 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 120.292 -0.563 . . . . 0.0 112.283 -179.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -67.58 -44.1 78.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.209 0.528 . . . . 0.0 110.398 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.6 tt -60.97 -26.45 67.56 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.668 -179.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -64.95 -48.94 65.68 Favored Glycine 0 C--N 1.332 0.356 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.7 p -63.34 -40.51 97.49 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 121.004 -0.278 . . . . 0.0 110.932 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 95.2 mt -63.51 -47.67 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.712 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.59 -51.73 56.87 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.9 m -59.82 -35.24 74.29 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.988 -0.285 . . . . 0.0 110.618 -179.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -62.62 -44.07 97.21 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.804 -0.359 . . . . 0.0 110.101 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.2 mt -80.03 -16.35 55.29 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.516 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.04 -26.16 65.3 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.65 -38.24 90.34 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.691 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.1 m -70.69 -39.75 73.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.998 0.428 . . . . 0.0 110.706 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.2 mt -63.92 -41.62 93.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.963 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -56.28 -40.12 73.76 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.971 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.18 -43.8 88.54 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.541 -0.837 . . . . 0.0 111.023 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -62.16 -47.41 84.66 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 179.186 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -59.57 -45.7 91.09 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.339 -0.545 . . . . 0.0 110.692 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.3 tttp -62.62 -51.72 66.17 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.708 -179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -59.9 -45.24 93.18 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.36 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.435 ' O ' ' C ' ' A' ' 44' ' ' SER . 15.1 mtp -75.58 -8.8 57.68 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.769 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 43' ' ' MET . 19.8 m 36.14 75.07 0.06 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.527 0.203 . . . . 0.0 110.871 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.546 ' CG ' ' H ' ' A' ' 46' ' ' ASP . 12.3 p-10 -56.01 -66.3 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.315 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.546 ' H ' ' CG ' ' A' ' 45' ' ' ASP . 98.9 m-20 -140.98 139.78 34.27 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.194 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -156.27 147.66 16.83 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.724 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -65.28 -22.23 60.71 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 120.962 1.108 . . . . 0.0 111.826 179.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 61.6 pttt . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.276 -179.372 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' FME . . . . . 0.455 ' O1 ' ' N ' ' A' ' 2' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.455 ' N ' ' O1 ' ' A' ' 1' ' ' FME . . . 81.24 11.61 83.26 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -61.42 -41.45 99.54 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 89.4 mt -112.24 127.47 69.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.858 0.361 . . . . 0.0 110.389 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.1 t -64.13 130.32 43.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.257 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.9 tt -65.34 -40.1 87.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.178 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.0 m95 -58.11 -29.44 65.5 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.904 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -63.01 -31.73 72.94 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.942 -0.703 . . . . 0.0 109.771 179.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.7 -39.1 73.66 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.383 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.5 mt -61.63 -48.22 81.86 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 111.825 0.306 . . . . 0.0 111.825 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.42 ' CG2' ' N ' ' A' ' 12' ' ' ILE . 19.6 tt -66.0 -43.34 92.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.201 -0.599 . . . . 0.0 110.169 -179.304 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.42 ' N ' ' CG2' ' A' ' 11' ' ' ILE . 86.3 mt -64.17 -43.44 97.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.611 179.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.43 -40.53 94.8 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.599 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.8 t -63.52 -45.32 98.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.784 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.451 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 79.9 mt -61.92 -44.62 99.13 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 C-N-CA 120.172 -0.611 . . . . 0.0 110.854 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 69.0 t -59.19 -44.59 92.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.401 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.6 t -63.44 -44.07 98.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.192 -179.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 34.2 mt -62.39 -48.57 79.14 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.576 -0.45 . . . . 0.0 112.156 -178.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.451 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 47.9 mt -63.91 -40.79 97.3 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.965 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -90.06 -13.73 35.29 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 121.202 -0.199 . . . . 0.0 111.51 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.33 163.36 0.04 OUTLIER Glycine 0 CA--C 1.532 1.124 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -68.79 -25.19 33.66 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.107 1.204 . . . . 0.0 114.443 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 tptp -67.19 -50.34 61.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.038 -0.665 . . . . 0.0 112.599 -178.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.6 mmtt -66.98 -45.44 77.65 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.343 -178.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 10.0 tt -62.35 -30.76 71.4 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.415 -179.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.85 -51.6 44.89 Favored Glycine 0 C--N 1.334 0.439 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.346 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 58.5 p -66.92 -41.54 86.89 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.01 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.414 HG23 HD13 ' A' ' 28' ' ' ILE . 94.6 mt -64.71 -47.91 86.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.921 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.86 -50.92 57.78 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 120.453 -0.879 . . . . 0.0 110.994 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p -60.71 -42.64 97.62 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.937 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -63.61 -45.42 90.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.891 0.377 . . . . 0.0 110.042 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.1 mt -79.26 -16.53 56.3 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.594 179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -87.18 5.65 84.75 Favored Glycine 0 CA--C 1.532 1.095 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.15 -38.19 78.63 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.122 0.461 . . . . 0.0 110.805 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 19.5 m -65.6 -43.51 89.43 Favored 'General case' 0 C--O 1.227 -0.123 0 CA-C-O 120.98 0.419 . . . . 0.0 110.7 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.3 mt -63.38 -41.92 94.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.116 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -57.6 -39.97 78.03 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.014 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.52 -41.14 90.7 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -61.3 -46.98 88.06 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.806 -0.358 . . . . 0.0 110.11 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -63.14 -45.48 91.71 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.703 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' ' O ' ' A' ' 44' ' ' SER . 4.4 tmtt? -61.94 -51.43 68.12 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.298 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.72 -46.13 77.78 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.443 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 2.7 mpp? -79.25 13.66 1.79 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 120.851 -0.34 . . . . 0.0 111.056 179.537 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 41' ' ' LYS . 40.0 t -137.97 144.86 41.37 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.458 ' OD1' ' N ' ' A' ' 45' ' ' ASP . 20.0 p-10 -88.32 -56.77 3.18 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 121.172 -0.211 . . . . 0.0 110.47 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.409 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 46.3 t0 -152.0 178.01 9.88 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 121.091 -0.244 . . . . 0.0 110.442 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.409 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 9.7 tp10 -171.07 92.78 0.44 Allowed Pre-proline 0 CA--C 1.538 0.511 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.856 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -54.54 -34.91 84.22 Favored 'Trans proline' 0 N--CA 1.494 1.518 0 C-N-CA 120.799 0.999 . . . . 0.0 111.803 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 99.5 mttt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.763 -179.745 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.74 168.06 41.92 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 61.48 38.19 95.37 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 86.0 mt -47.66 -90.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.2 p -78.59 168.23 20.08 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.4 tt -63.17 -37.97 80.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.025 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 3.6 m95 -57.96 -28.82 64.67 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.917 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -63.39 -31.91 73.2 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.0 mt -71.53 -37.71 71.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.142 -0.623 . . . . 0.0 110.464 179.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.6 mt -62.23 -47.48 84.23 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -178.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.418 ' CG2' ' N ' ' A' ' 12' ' ' ILE . 20.6 tt -67.19 -42.91 88.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.227 -179.334 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.418 ' N ' ' CG2' ' A' ' 11' ' ' ILE . 94.9 mt -63.68 -43.45 98.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.312 179.398 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.0 -38.64 83.2 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.891 0.377 . . . . 0.0 110.432 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.76 -42.94 96.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.079 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.435 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.1 mt -60.77 -43.93 96.33 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.568 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.689 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 44.9 t -57.88 -43.98 85.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.387 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.496 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.6 t -63.18 -43.44 98.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.086 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 34.0 mt -62.82 -48.54 78.65 Favored 'General case' 0 C--N 1.33 -0.26 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.751 -178.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.435 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.3 mt -64.01 -42.06 97.26 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.667 -179.074 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' A' ' 21' ' ' GLY . 38.9 m-85 -85.47 -12.99 50.5 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 121.143 -0.223 . . . . 0.0 111.595 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.62 159.12 0.01 OUTLIER Glycine 0 CA--C 1.54 1.641 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -70.24 -22.5 29.78 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.465 1.444 . . . . 0.0 114.625 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -67.73 -52.33 38.79 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 120.449 -0.501 . . . . 0.0 112.256 -179.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 42.5 tttp -66.29 -44.61 83.03 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 120.447 -0.501 . . . . 0.0 110.443 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt -62.91 -25.69 68.44 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.653 -179.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.02 -50.38 58.05 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -65.85 -39.31 90.65 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.892 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.424 HD13 HG23 ' A' ' 28' ' ' ILE . 96.9 mt -63.69 -47.76 89.7 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.723 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -61.62 -50.77 62.9 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.0 m -59.69 -37.57 79.2 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 121.03 -0.268 . . . . 0.0 110.672 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -63.36 -44.91 93.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.933 0.397 . . . . 0.0 110.092 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.8 mt -81.22 -18.8 44.85 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.579 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -66.11 -10.72 53.04 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -67.9 -38.3 82.79 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.693 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.9 m -68.17 -39.54 82.52 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.096 0.474 . . . . 0.0 110.517 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 89.9 mt -63.95 -41.75 93.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.103 179.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -56.57 -41.97 77.81 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.231 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.92 -43.12 84.0 Favored Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.512 -0.851 . . . . 0.0 110.998 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -62.3 -46.68 87.67 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 38.5 ttmt -62.17 -45.35 93.81 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.433 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.42 ' O ' ' OG ' ' A' ' 44' ' ' SER . 30.9 ttpt -60.31 -51.62 68.75 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.724 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.18 -44.03 87.81 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 119.574 -0.851 . . . . 0.0 111.21 179.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 24.4 mtm -77.6 12.77 1.49 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 121.089 -0.244 . . . . 0.0 110.844 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 41' ' ' LYS . 97.0 p -71.02 -17.74 62.61 Favored 'General case' 0 CA--C 1.526 0.049 0 CA-C-O 120.816 0.341 . . . . 0.0 110.557 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -62.21 -42.23 99.11 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.337 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -135.52 66.07 1.53 Allowed 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -168.88 90.63 0.6 Allowed Pre-proline 0 CA--C 1.538 0.481 0 C-N-CA 120.355 -0.538 . . . . 0.0 110.848 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -54.79 -38.93 91.82 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 120.917 1.078 . . . . 0.0 111.836 179.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 64.5 tttm . . . . . 0 C--N 1.332 -0.193 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.362 -179.89 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -69.1 149.12 48.69 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.07 35.17 0.72 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.949 -0.861 . . . . 0.0 110.949 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.415 HD13 HG21 ' A' ' 4' ' ' ILE . 86.0 mt -62.57 -43.98 98.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.9 t -96.41 123.28 40.0 Favored 'General case' 0 N--CA 1.463 0.195 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 tt -66.35 -40.4 86.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.278 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 3.3 m95 -58.39 -28.44 65.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.209 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 64.4 tp60 -63.68 -32.0 73.35 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 120.229 -0.588 . . . . 0.0 109.545 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 95.9 mt -70.89 -38.51 73.03 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 119.955 -0.698 . . . . 0.0 110.509 179.092 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.6 mt -62.12 -47.91 82.49 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -178.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.407 ' CG2' ' N ' ' A' ' 12' ' ' ILE . 19.7 tt -66.01 -42.69 92.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 C-N-CA 120.356 -0.538 . . . . 0.0 110.181 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.407 ' N ' ' CG2' ' A' ' 11' ' ' ILE . 83.2 mt -64.28 -43.78 97.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 120.671 -0.412 . . . . 0.0 110.598 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.23 -40.6 94.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.456 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.0 t -62.47 -44.17 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.067 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.449 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.6 mt -61.87 -44.96 99.59 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.612 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.936 -179.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 52.1 t -58.84 -44.22 90.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.473 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' GLY . 73.5 t -63.63 -43.38 98.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.71 -0.396 . . . . 0.0 111.249 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 37.2 mt -63.16 -48.47 78.3 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.98 -178.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 42.3 mt -64.19 -41.02 97.26 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.872 -179.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 21' ' ' GLY . 44.7 m-85 -88.89 -12.28 42.21 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 111.609 0.226 . . . . 0.0 111.609 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.42 161.26 0.02 OUTLIER Glycine 0 CA--C 1.54 1.63 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.25 -24.96 26.85 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 121.466 1.444 . . . . 0.0 114.718 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.76 -51.18 58.83 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 120.398 -0.521 . . . . 0.0 112.371 -178.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -67.28 -45.02 77.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt -61.0 -29.1 69.5 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.716 -178.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.03 -50.72 56.36 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -65.26 -40.85 94.52 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.839 -0.344 . . . . 0.0 110.858 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.61 -47.57 90.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.668 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.529 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.05 -49.9 67.93 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.7 t -59.54 -43.1 93.59 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 121.039 -0.265 . . . . 0.0 110.585 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -62.03 -45.47 93.45 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.096 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.4 mt -79.18 -21.54 46.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.682 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -81.85 -0.24 89.18 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.565 -0.614 . . . . 0.0 111.565 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.97 -38.36 85.94 Favored 'General case' 0 CA--C 1.527 0.072 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.857 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 38.3 t -65.21 -40.51 94.24 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.091 0.472 . . . . 0.0 110.54 179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.9 mt -61.81 -41.2 89.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.995 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -57.37 -41.32 79.92 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.057 -179.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.01 -38.87 94.5 Favored Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.592 -0.813 . . . . 0.0 111.106 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.456 ' O ' ' CE ' ' A' ' 43' ' ' MET . 5.5 m-85 -62.13 -47.67 83.56 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -64.98 -46.5 81.19 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.771 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -58.88 -49.02 79.33 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 120.51 -0.476 . . . . 0.0 110.942 -179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.96 -46.79 75.06 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 119.49 -0.884 . . . . 0.0 111.144 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.456 ' CE ' ' O ' ' A' ' 39' ' ' PHE . 3.4 mpp? -78.23 12.94 1.66 Allowed 'General case' 0 CA--C 1.534 0.342 0 O-C-N 122.209 -0.307 . . . . 0.0 110.787 179.386 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 22.7 t -144.32 43.05 1.41 Allowed 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 120.756 0.312 . . . . 0.0 110.418 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -61.77 -44.69 96.39 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.777 -0.369 . . . . 0.0 110.451 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.554 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 38.0 t70 -82.19 -178.2 6.93 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.554 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 1.2 pm0 -153.32 79.6 5.48 Favored Pre-proline 0 CA--C 1.536 0.437 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.126 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -74.66 155.8 44.57 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 120.942 1.094 . . . . 0.0 112.011 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 65.1 tttm . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.218 179.395 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.08 0 CA-C-O 120.715 0.293 . . . . 0.0 110.415 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -62.55 -43.6 98.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.083 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.497 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -62.32 -44.46 99.2 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.68 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.768 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 45.1 t -58.9 -45.21 91.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.428 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.4 t -62.62 -43.43 98.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.218 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.0 mt -63.29 -48.16 79.29 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.989 -178.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.497 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.1 mt -63.96 -41.69 97.5 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.504 -0.479 . . . . 0.0 110.767 -178.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -87.93 -12.77 43.66 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.58 161.5 0.03 OUTLIER Glycine 0 CA--C 1.54 1.636 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -70.0 -25.13 27.78 Favored 'Trans proline' 0 N--CA 1.502 1.994 0 C-N-CA 121.5 1.467 . . . . 0.0 114.572 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -66.72 -50.7 61.95 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.342 -0.543 . . . . 0.0 112.416 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -67.3 -44.97 77.89 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.534 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt . . . . . 0 C--N 1.324 -0.525 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.773 -179.128 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.764 0.316 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 52.9 t -63.71 -44.09 98.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.088 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 78.9 mt -61.53 -44.54 98.78 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.732 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.5 t -57.7 -43.77 84.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 C-N-CA 120.29 -0.564 . . . . 0.0 110.344 -179.347 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.8 t -63.86 -43.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.186 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 36.0 mt -62.73 -49.13 76.25 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.811 -178.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.47 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 36.3 mt -62.73 -42.33 99.61 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.326 -0.55 . . . . 0.0 110.626 -178.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -87.23 -14.1 42.01 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 121.062 -0.255 . . . . 0.0 111.676 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.54 161.96 0.04 OUTLIER Glycine 0 CA--C 1.543 1.807 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -68.87 -20.9 38.58 Favored 'Trans proline' 0 N--CA 1.504 2.141 0 C-N-CA 121.58 1.52 . . . . 0.0 114.772 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -69.21 -50.86 43.46 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -67.66 -47.09 70.52 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.355 -0.538 . . . . 0.0 110.477 -179.309 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt . . . . . 0 C--N 1.324 -0.531 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.702 -179.174 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.852 0.358 . . . . 0.0 110.389 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.6 t -60.75 -43.01 94.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.03 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -59.8 -43.37 91.65 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.592 0 C-N-CA 120.167 -0.613 . . . . 0.0 110.698 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.0 t -57.0 -43.84 81.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.386 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.6 t -61.99 -44.07 98.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.194 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.1 mt -62.76 -48.0 81.06 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.757 -178.719 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.474 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 29.1 mt -63.88 -41.69 97.68 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.613 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' A' ' 21' ' ' GLY . 40.5 m-85 -86.81 -13.07 46.15 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 111.57 0.211 . . . . 0.0 111.57 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.13 160.28 0.02 OUTLIER Glycine 0 CA--C 1.54 1.631 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.469 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.76 -16.27 33.36 Favored 'Trans proline' 0 N--CA 1.502 2.029 0 C-N-CA 121.502 1.468 . . . . 0.0 114.507 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.0 ttpt -67.48 -52.72 35.97 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -68.56 -47.54 66.58 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.533 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--N 1.325 -0.497 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.581 -179.185 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.761 0.315 . . . . 0.0 110.351 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.8 t -62.51 -44.14 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.026 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.482 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.7 mt -61.58 -44.77 99.19 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.75 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.5 t -58.79 -44.44 90.31 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.528 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.2 t -63.15 -43.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.229 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.9 mt -62.95 -48.23 79.79 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.944 -178.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -64.11 -40.55 96.46 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.87 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -88.69 -14.65 36.81 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 111.637 0.236 . . . . 0.0 111.637 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 60.76 160.54 0.09 OUTLIER Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -70.28 -27.66 23.7 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.461 1.441 . . . . 0.0 114.666 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -65.84 -49.78 66.95 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -67.12 -44.99 78.52 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.434 -179.122 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.1 tt . . . . . 0 C--N 1.324 -0.516 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.78 -179.174 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.14 0 CA-C-O 120.842 0.354 . . . . 0.0 110.307 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 40.4 t -60.83 -43.1 94.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.944 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.463 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.4 mt -60.67 -44.04 96.2 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.533 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.751 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.8 t -57.67 -44.32 85.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.389 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.0 t -62.71 -43.81 98.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.238 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.406 HD23 ' HA ' ' A' ' 18' ' ' LEU . 35.3 mt -62.69 -48.12 80.67 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.729 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -63.6 -42.05 98.27 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.467 -0.493 . . . . 0.0 110.757 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.9 m-85 -86.77 -12.07 49.18 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.509 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.18 160.21 0.01 OUTLIER Glycine 0 CA--C 1.543 1.806 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -72.82 -12.73 26.55 Favored 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 121.434 1.423 . . . . 0.0 114.544 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.52 -55.13 12.73 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 120.301 -0.559 . . . . 0.0 112.338 -179.163 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -68.82 -46.9 67.42 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.175 0.512 . . . . 0.0 110.584 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.455 HD23 ' O ' ' A' ' 25' ' ' LEU . 8.8 tt . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.68 -178.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.797 0.332 . . . . 0.0 110.458 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -62.39 -45.54 98.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.202 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 74.3 mt -61.79 -45.46 98.65 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.644 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.806 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.1 t -58.48 -44.22 88.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.49 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.529 ' O ' ' N ' ' A' ' 21' ' ' GLY . 75.5 t -63.72 -43.33 97.99 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.202 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 18' ' ' LEU . 35.7 mt -63.13 -48.31 79.07 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.922 -178.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.8 mt -64.35 -41.89 96.51 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.757 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 21' ' ' GLY . 45.6 m-85 -88.35 -12.01 44.61 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.13 162.23 0.02 OUTLIER Glycine 0 CA--C 1.542 1.748 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -69.46 -25.52 29.89 Favored 'Trans proline' 0 N--CA 1.503 2.03 0 C-N-CA 121.505 1.47 . . . . 0.0 114.74 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.67 -50.59 62.41 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 120.324 -0.551 . . . . 0.0 112.366 -178.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 31.8 mmtp -67.07 -45.3 77.73 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.387 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.4 tt . . . . . 0 C--N 1.324 -0.507 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.732 -179.232 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.784 0.326 . . . . 0.0 110.546 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.4 t -64.03 -43.27 97.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.071 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.471 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 77.8 mt -61.04 -43.93 97.2 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.744 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.39 -44.31 84.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.377 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.1 t -63.44 -43.56 98.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.119 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.9 mt -62.83 -48.63 78.25 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.75 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.1 mt -63.9 -42.78 97.36 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.666 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.416 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.1 m-85 -86.19 -13.69 46.22 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.622 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 55.87 163.2 0.02 OUTLIER Glycine 0 CA--C 1.541 1.687 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -70.14 -19.62 34.07 Favored 'Trans proline' 0 N--CA 1.501 1.936 0 C-N-CA 121.584 1.523 . . . . 0.0 114.583 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -67.8 -52.23 39.46 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 120.292 -0.563 . . . . 0.0 112.283 -179.269 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -67.58 -44.1 78.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.209 0.528 . . . . 0.0 110.398 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.6 tt . . . . . 0 C--N 1.327 -0.402 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.668 -179.04 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.164 0 CA-C-O 120.745 0.307 . . . . 0.0 110.599 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.8 t -63.52 -45.32 98.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.784 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.473 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 79.9 mt -61.92 -44.62 99.13 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 C-N-CA 120.172 -0.611 . . . . 0.0 110.854 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 69.0 t -59.19 -44.59 92.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.401 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.6 t -63.44 -44.07 98.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.192 -179.65 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.2 mt -62.39 -48.57 79.14 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.576 -0.45 . . . . 0.0 112.156 -178.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.473 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 47.9 mt -63.91 -40.79 97.3 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.965 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -90.06 -13.73 35.29 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 121.202 -0.199 . . . . 0.0 111.51 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.33 163.36 0.04 OUTLIER Glycine 0 CA--C 1.532 1.124 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -68.79 -25.19 33.66 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.107 1.204 . . . . 0.0 114.443 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 tptp -67.19 -50.34 61.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.038 -0.665 . . . . 0.0 112.599 -178.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.6 mmtt -66.98 -45.44 77.65 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.343 -178.693 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 10.0 tt . . . . . 0 C--N 1.324 -0.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.415 -179.1 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.891 0.377 . . . . 0.0 110.432 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.76 -42.94 96.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.079 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.458 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.1 mt -60.77 -43.93 96.33 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.568 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.689 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 44.9 t -57.88 -43.98 85.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.387 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.496 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.6 t -63.18 -43.44 98.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.086 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.0 mt -62.82 -48.54 78.65 Favored 'General case' 0 C--N 1.33 -0.26 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.751 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.458 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.3 mt -64.01 -42.06 97.26 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.667 -179.074 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' A' ' 21' ' ' GLY . 38.9 m-85 -85.47 -12.99 50.5 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 121.143 -0.223 . . . . 0.0 111.595 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.62 159.12 0.01 OUTLIER Glycine 0 CA--C 1.54 1.641 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -70.24 -22.5 29.78 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.465 1.444 . . . . 0.0 114.625 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -67.73 -52.33 38.79 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 120.449 -0.501 . . . . 0.0 112.256 -179.07 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 42.5 tttp -66.29 -44.61 83.03 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 120.447 -0.501 . . . . 0.0 110.443 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt . . . . . 0 C--N 1.324 -0.538 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.653 -179.11 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.121 0 CA-C-O 120.814 0.34 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.0 t -62.47 -44.17 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.067 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.475 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.6 mt -61.87 -44.96 99.59 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.612 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.936 -179.35 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 52.1 t -58.84 -44.22 90.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.473 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' GLY . 73.5 t -63.63 -43.38 98.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.71 -0.396 . . . . 0.0 111.249 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 18' ' ' LEU . 37.2 mt -63.16 -48.47 78.3 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.98 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 42.3 mt -64.19 -41.02 97.26 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.872 -179.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 21' ' ' GLY . 44.7 m-85 -88.89 -12.28 42.21 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 111.609 0.226 . . . . 0.0 111.609 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.42 161.26 0.02 OUTLIER Glycine 0 CA--C 1.54 1.63 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.25 -24.96 26.85 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 121.466 1.444 . . . . 0.0 114.718 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.76 -51.18 58.83 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 120.398 -0.521 . . . . 0.0 112.371 -178.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -67.28 -45.02 77.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt . . . . . 0 C--N 1.324 -0.506 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.716 -178.948 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.27 -36.64 93.47 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 153.47 19.72 0.05 OUTLIER Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 74.4 mt -64.65 -25.05 36.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.055 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.2 t -65.06 130.4 43.21 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.107 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.3 tt -65.15 -40.67 89.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.1 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -58.84 -31.68 68.73 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.161 179.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -64.23 -38.38 90.83 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.252 -0.579 . . . . 0.0 109.74 179.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 69.2 mt -70.62 -36.26 73.39 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.184 -0.607 . . . . 0.0 110.587 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.402 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.2 tt -62.43 -48.27 80.43 Favored 'General case' 0 C--O 1.23 0.067 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -178.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.464 HG23 ' N ' ' A' ' 12' ' ' ILE . 20.0 tt -67.05 -42.17 88.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.024 -178.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.464 ' N ' HG23 ' A' ' 11' ' ' ILE . 95.1 mt -63.52 -43.48 98.34 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.134 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.24 179.519 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.29 -39.2 82.21 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.415 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.0 t -62.55 -43.6 98.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.083 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.497 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -62.32 -44.46 99.2 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.68 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.768 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 45.1 t -58.9 -45.21 91.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.428 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.4 t -62.62 -43.43 98.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.218 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.0 mt -63.29 -48.16 79.29 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.989 -178.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.497 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.1 mt -63.96 -41.69 97.5 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.504 -0.479 . . . . 0.0 110.767 -178.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -87.93 -12.77 43.66 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.58 161.5 0.03 OUTLIER Glycine 0 CA--C 1.54 1.636 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -70.0 -25.13 27.78 Favored 'Trans proline' 0 N--CA 1.502 1.994 0 C-N-CA 121.5 1.467 . . . . 0.0 114.572 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -66.72 -50.7 61.95 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.342 -0.543 . . . . 0.0 112.416 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -67.3 -44.97 77.89 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.534 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt -61.56 -29.85 70.28 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.773 -179.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.98 -51.06 48.48 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.0 p -66.13 -41.36 90.57 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.876 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 92.7 mt -64.61 -46.91 91.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.703 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.77 -51.05 56.92 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.6 t -60.28 -42.03 94.58 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.981 -0.288 . . . . 0.0 110.734 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -62.36 -45.36 93.53 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.014 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 74.8 mt -80.51 -20.25 44.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.559 179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -82.93 1.15 89.08 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -67.13 -35.73 80.37 Favored 'General case' 0 C--O 1.231 0.115 0 O-C-N 122.566 -0.373 . . . . 0.0 110.903 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.9 p -67.72 -37.97 82.95 Favored 'General case' 0 C--O 1.224 -0.271 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.526 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 88.8 mt -62.48 -41.16 90.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.037 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -56.66 -38.13 71.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.025 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.95 -38.19 92.67 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -61.99 -45.59 92.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.878 0.371 . . . . 0.0 110.037 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.0 tttp -64.53 -46.08 84.42 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.525 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -59.38 -50.41 74.05 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 120.608 -0.437 . . . . 0.0 110.607 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.96 -43.59 77.64 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.958 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 37.3 mtm -75.75 0.88 16.34 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 120.994 -0.283 . . . . 0.0 110.593 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 59.2 p -67.91 -38.02 82.43 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.815 0.341 . . . . 0.0 110.58 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -63.11 -41.74 99.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.367 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.489 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 38.8 t70 -78.21 177.35 8.46 Favored 'General case' 0 C--O 1.232 0.146 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.628 ' N ' ' OE2' ' A' ' 47' ' ' GLU . 0.8 OUTLIER -153.62 80.91 5.0 Favored Pre-proline 0 CA--C 1.536 0.42 0 C-N-CA 120.803 -0.359 . . . . 0.0 111.6 179.958 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -53.23 -36.9 79.52 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 120.808 1.005 . . . . 0.0 111.718 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 20.9 ptmt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.089 -179.843 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.53 62.98 3.76 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -155.53 147.56 16.58 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.868 -0.893 . . . . 0.0 110.868 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 78.5 mt -107.21 123.77 62.62 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.079 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.5 t -74.58 128.63 36.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.994 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.3 tt -65.96 -40.42 87.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.938 0.399 . . . . 0.0 110.215 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 3.6 m95 -60.81 -30.02 69.82 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.294 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.401 ' O ' HG22 ' A' ' 11' ' ' ILE . 25.3 mm-40 -63.16 -34.76 78.33 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.213 -0.595 . . . . 0.0 109.788 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 66.3 mt -71.62 -35.06 70.33 Favored 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.074 -0.65 . . . . 0.0 110.594 179.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.406 ' O ' HG23 ' A' ' 14' ' ' VAL . 3.2 mt -62.18 -46.29 89.62 Favored 'General case' 0 CA--C 1.526 0.046 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -178.002 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.481 HG23 ' N ' ' A' ' 12' ' ' ILE . 16.9 tt -64.82 -42.97 96.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.994 -178.565 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.481 ' N ' HG23 ' A' ' 11' ' ' ILE . 81.2 mt -64.73 -42.91 96.3 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.385 179.681 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.9 -41.1 97.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.764 0.316 . . . . 0.0 110.424 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 10' ' ' LEU . 52.9 t -63.71 -44.09 98.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.088 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 78.9 mt -61.53 -44.54 98.78 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.732 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.5 t -57.7 -43.77 84.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 C-N-CA 120.29 -0.564 . . . . 0.0 110.344 -179.347 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.8 t -63.86 -43.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.186 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 36.0 mt -62.73 -49.13 76.25 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.811 -178.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.47 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 36.3 mt -62.73 -42.33 99.61 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.326 -0.55 . . . . 0.0 110.626 -178.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -87.23 -14.1 42.01 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 121.062 -0.255 . . . . 0.0 111.676 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.54 161.96 0.04 OUTLIER Glycine 0 CA--C 1.543 1.807 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -68.87 -20.9 38.58 Favored 'Trans proline' 0 N--CA 1.504 2.141 0 C-N-CA 121.58 1.52 . . . . 0.0 114.772 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -69.21 -50.86 43.46 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -67.66 -47.09 70.52 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.355 -0.538 . . . . 0.0 110.477 -179.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt -61.21 -27.8 68.69 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.702 -179.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.12 -50.81 55.41 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 46.2 t -65.53 -41.08 93.5 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.713 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.88 -47.07 92.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.187 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.849 -179.571 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.38 -51.22 56.35 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 72.5 p -59.86 -42.03 92.78 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 121.009 -0.276 . . . . 0.0 110.828 -179.119 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -61.27 -45.75 93.2 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.093 179.608 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.9 mt -80.34 -19.84 45.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.707 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -74.84 -1.52 62.53 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 -179.508 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.25 -34.55 78.36 Favored 'General case' 0 C--N 1.332 -0.175 0 C-N-CA 120.769 -0.373 . . . . 0.0 110.522 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.7 m -65.37 -34.01 77.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.022 0.439 . . . . 0.0 110.563 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.6 mt -61.84 -40.78 88.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.949 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -56.94 -41.65 78.62 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.076 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.21 -37.67 93.16 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -62.3 -45.78 91.72 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -63.06 -46.26 88.31 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.435 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -58.91 -51.29 70.69 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 120.421 -0.512 . . . . 0.0 110.561 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.45 -44.27 80.32 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.136 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 16.8 mtm -77.06 12.5 1.39 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 121.133 -0.227 . . . . 0.0 110.622 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 60.5 p -133.01 4.93 3.83 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 120.888 0.375 . . . . 0.0 110.771 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -127.95 -75.65 0.57 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.41 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.497 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 37.7 t70 -163.15 179.25 7.6 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.071 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.497 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 7.6 mp0 -141.33 81.17 15.8 Favored Pre-proline 0 CA--C 1.54 0.577 0 C-N-CA 120.659 -0.417 . . . . 0.0 111.38 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -52.9 -38.21 78.63 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 121.031 1.154 . . . . 0.0 111.828 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 C--N 1.332 -0.158 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.225 -179.669 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.24 13.11 81.35 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 82.72 2.99 90.69 Favored Glycine 0 CA--C 1.521 0.409 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 93.4 mt -103.89 114.03 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-O 120.746 0.308 . . . . 0.0 110.342 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.4 t -77.11 160.79 28.77 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.935 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.3 tt -64.99 -39.05 84.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.931 0.396 . . . . 0.0 110.226 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.4 m95 -58.84 -29.09 66.67 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.038 179.371 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -62.52 -30.5 71.33 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.181 -0.608 . . . . 0.0 109.461 179.469 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.403 HD23 ' HA ' ' A' ' 9' ' ' LEU . 96.7 mt -71.64 -37.86 70.8 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 120.072 -0.651 . . . . 0.0 110.627 178.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.43 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.4 mt -62.26 -47.47 84.23 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 111.959 0.355 . . . . 0.0 111.959 -178.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.476 HG23 ' N ' ' A' ' 12' ' ' ILE . 20.2 tt -65.91 -42.56 92.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.035 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.476 ' N ' HG23 ' A' ' 11' ' ' ILE . 92.6 mt -63.17 -42.85 98.06 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.151 0 C-N-CA 120.751 -0.38 . . . . 0.0 110.232 179.282 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.81 -38.17 84.5 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.852 0.358 . . . . 0.0 110.389 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 10' ' ' LEU . 39.6 t -60.75 -43.01 94.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.03 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -59.8 -43.37 91.65 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.592 0 C-N-CA 120.167 -0.613 . . . . 0.0 110.698 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.0 t -57.0 -43.84 81.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.386 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.6 t -61.99 -44.07 98.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.194 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.1 mt -62.76 -48.0 81.06 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.757 -178.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.474 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 29.1 mt -63.88 -41.69 97.68 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.613 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' A' ' 21' ' ' GLY . 40.5 m-85 -86.81 -13.07 46.15 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 111.57 0.211 . . . . 0.0 111.57 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.13 160.28 0.02 OUTLIER Glycine 0 CA--C 1.54 1.631 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.469 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.76 -16.27 33.36 Favored 'Trans proline' 0 N--CA 1.502 2.029 0 C-N-CA 121.502 1.468 . . . . 0.0 114.507 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.0 ttpt -67.48 -52.72 35.97 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -68.56 -47.54 66.58 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.533 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.87 -26.69 68.9 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.581 -179.185 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -66.22 -51.13 46.46 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -66.98 -41.74 86.28 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.791 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.02 -47.96 88.08 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.148 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.725 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.02 -50.87 59.78 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.054 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.2 m -60.64 -39.94 90.11 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 121.171 -0.211 . . . . 0.0 110.893 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -63.49 -45.31 91.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.89 0.376 . . . . 0.0 110.103 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.2 mt -79.11 -14.85 58.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.59 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -82.93 3.82 82.52 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -67.4 -37.65 83.45 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.795 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 78.1 p -68.82 -38.81 80.15 Favored 'General case' 0 C--O 1.224 -0.256 0 CA-C-O 121.049 0.452 . . . . 0.0 110.703 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.2 mt -63.4 -41.61 93.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.018 179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -56.58 -42.62 78.96 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.14 -178.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.96 -41.32 97.41 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.112 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -61.76 -45.75 92.56 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -64.25 -46.41 83.87 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.513 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -59.82 -50.53 73.43 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 120.599 -0.44 . . . . 0.0 110.713 -179.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.13 -42.06 76.3 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.079 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 25.1 mtm -76.53 13.6 0.95 Allowed 'General case' 0 CA--C 1.536 0.442 0 O-C-N 122.238 -0.289 . . . . 0.0 110.74 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 35.2 t -76.26 -3.95 39.33 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.686 0.279 . . . . 0.0 110.459 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -62.4 -39.9 94.75 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.458 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 45.9 t0 58.95 177.06 0.07 Allowed 'General case' 0 C--O 1.231 0.123 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -155.98 147.9 17.29 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.816 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -64.93 -23.98 61.19 Favored 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 120.99 1.127 . . . . 0.0 111.9 179.003 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 62.8 mttp . . . . . 0 C--N 1.332 -0.192 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.387 -179.658 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.2 -38.55 96.68 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -169.55 168.96 41.72 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 96.1 mt -85.37 126.59 40.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.9 t -84.23 128.33 34.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.198 -0.455 . . . . 0.0 109.862 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.5 tt -64.58 -40.52 89.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.168 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -58.51 -30.9 67.41 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.01 179.354 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -65.23 -37.64 87.89 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 179.119 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 90.4 mt -70.81 -36.96 73.2 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.122 -0.631 . . . . 0.0 110.17 178.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.424 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.8 tt -62.54 -48.42 79.6 Favored 'General case' 0 CA--C 1.527 0.092 0 N-CA-C 112.06 0.393 . . . . 0.0 112.06 -178.119 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.475 HG23 ' N ' ' A' ' 12' ' ' ILE . 19.5 tt -66.06 -42.62 91.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.052 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.475 ' N ' HG23 ' A' ' 11' ' ' ILE . 95.2 mt -63.71 -42.92 97.62 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.403 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.37 -38.62 84.48 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.351 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 10' ' ' LEU . 44.8 t -62.51 -44.14 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.026 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.482 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.7 mt -61.58 -44.77 99.19 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.75 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.5 t -58.79 -44.44 90.31 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.528 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.2 t -63.15 -43.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.229 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.9 mt -62.95 -48.23 79.79 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.944 -178.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -64.11 -40.55 96.46 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.87 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -88.69 -14.65 36.81 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 111.637 0.236 . . . . 0.0 111.637 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 60.76 160.54 0.09 OUTLIER Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -70.28 -27.66 23.7 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.461 1.441 . . . . 0.0 114.666 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -65.84 -49.78 66.95 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -67.12 -44.99 78.52 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.434 -179.122 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.1 tt -61.37 -29.56 69.98 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.78 -179.174 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.46 -50.99 52.34 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 39.1 m -64.25 -40.55 96.24 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.852 179.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.6 mt -64.49 -47.61 88.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.731 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.447 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -61.83 -50.97 60.57 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 120.395 -0.907 . . . . 0.0 110.875 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 76.1 p -60.57 -39.81 89.37 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 121.054 -0.259 . . . . 0.0 110.848 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -62.24 -45.6 92.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.916 0.388 . . . . 0.0 110.155 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.4 mt -80.2 -18.19 50.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.743 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -77.49 1.31 66.51 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.38 -36.27 82.43 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.886 0.374 . . . . 0.0 110.921 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 36.5 t -66.38 -36.91 84.06 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.514 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 86.0 mt -61.73 -40.76 87.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.206 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -56.28 -38.87 71.78 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.036 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.34 -36.48 91.71 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -62.78 -47.01 85.34 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.019 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -63.39 -46.58 85.77 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.525 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -58.78 -50.77 72.72 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.713 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.23 -44.85 79.97 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 119.681 -0.808 . . . . 0.0 111.196 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.429 ' O ' ' O ' ' A' ' 44' ' ' SER . 34.1 ttm -77.57 13.4 1.28 Allowed 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 121.082 -0.247 . . . . 0.0 110.841 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.486 ' HG ' ' HB3' ' A' ' 47' ' ' GLU . 10.6 t 58.25 151.87 0.01 OUTLIER 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.678 0.275 . . . . 0.0 110.682 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -85.65 -89.21 0.11 Allowed 'General case' 0 CA--C 1.524 -0.028 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.422 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -97.57 48.96 1.03 Allowed 'General case' 0 C--N 1.339 0.136 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.252 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.486 ' HB3' ' HG ' ' A' ' 44' ' ' SER . 39.0 tt0 -165.3 90.15 0.94 Allowed Pre-proline 0 CA--C 1.536 0.438 0 C-N-CA 120.434 -0.507 . . . . 0.0 111.091 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -59.91 145.74 97.56 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 120.881 1.054 . . . . 0.0 111.736 179.318 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt . . . . . 0 N--CA 1.463 0.21 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.143 179.641 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' FME . . . . . 0.564 ' N ' ' SD ' ' A' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.77 -39.09 97.1 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -83.58 -163.92 35.75 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 92.0 mt -87.07 114.96 27.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 121.004 0.43 . . . . 0.0 110.046 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.4 t -70.6 150.07 46.43 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.095 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.8 tt -64.53 -37.81 81.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.018 0.437 . . . . 0.0 110.102 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.1 m95 -58.37 -29.53 66.07 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.866 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 -62.07 -31.71 72.17 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.009 -0.676 . . . . 0.0 109.634 179.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 9' ' ' LEU . 97.6 mt -70.87 -37.37 73.06 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.66 179.013 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.423 ' O ' HG23 ' A' ' 14' ' ' VAL . 3.2 mt -62.09 -46.51 88.75 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.449 HG23 ' N ' ' A' ' 12' ' ' ILE . 14.6 tt -67.18 -42.42 88.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.282 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.449 ' N ' HG23 ' A' ' 11' ' ' ILE . 82.6 mt -62.84 -43.33 98.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.275 179.054 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.82 -38.32 81.68 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.842 0.354 . . . . 0.0 110.307 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 10' ' ' LEU . 40.4 t -60.83 -43.1 94.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.944 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.463 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.4 mt -60.67 -44.04 96.2 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.533 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.751 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.8 t -57.67 -44.32 85.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.389 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.0 t -62.71 -43.81 98.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.238 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.406 HD23 ' HA ' ' A' ' 18' ' ' LEU . 35.3 mt -62.69 -48.12 80.67 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.729 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -63.6 -42.05 98.27 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.467 -0.493 . . . . 0.0 110.757 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.9 m-85 -86.77 -12.07 49.18 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.509 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.18 160.21 0.01 OUTLIER Glycine 0 CA--C 1.543 1.806 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -72.82 -12.73 26.55 Favored 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 121.434 1.423 . . . . 0.0 114.544 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.52 -55.13 12.73 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 120.301 -0.559 . . . . 0.0 112.338 -179.163 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -68.82 -46.9 67.42 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.175 0.512 . . . . 0.0 110.584 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.455 HD23 ' O ' ' A' ' 25' ' ' LEU . 8.8 tt -63.49 -23.54 67.44 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.68 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.59 -51.57 35.54 Favored Glycine 0 C--N 1.333 0.381 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 9.5 t -65.69 -43.02 90.48 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.037 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.7 mt -64.34 -47.68 88.57 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.976 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -64.44 -50.94 56.52 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.009 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 13.1 t -59.69 -41.91 91.78 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 121.111 -0.236 . . . . 0.0 110.66 -179.021 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -63.44 -46.18 87.48 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 120.691 -0.403 . . . . 0.0 110.381 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 69.0 mt -79.51 -20.98 45.9 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.669 179.322 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -82.17 0.65 88.53 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 111.558 -0.617 . . . . 0.0 111.558 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.72 -39.31 87.95 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.672 -179.545 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.5 m -69.54 -43.96 71.9 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.007 0.432 . . . . 0.0 110.793 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.5 mt -63.1 -41.36 92.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.012 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 66.6 tttm -56.44 -42.89 78.85 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.822 -0.627 . . . . 0.0 111.014 -178.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.22 -44.81 96.51 Favored Glycine 0 CA--C 1.522 0.489 0 C-N-CA 120.341 -0.933 . . . . 0.0 110.773 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -63.39 -44.88 93.42 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 178.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -60.04 -46.0 90.97 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.472 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -65.39 -53.29 45.39 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.971 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -59.8 -31.58 69.83 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 119.756 -0.778 . . . . 0.0 111.184 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.496 ' O ' ' N ' ' A' ' 45' ' ' ASP . 32.1 mmm -75.28 13.2 0.76 Allowed 'General case' 0 N--CA 1.453 -0.297 0 O-C-N 122.387 -0.196 . . . . 0.0 110.723 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 12.6 t 46.25 14.14 0.02 OUTLIER 'General case' 0 C--O 1.231 0.111 0 C-N-CA 120.962 -0.295 . . . . 0.0 110.724 179.309 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.496 ' N ' ' O ' ' A' ' 43' ' ' MET . 35.6 t70 -60.62 -43.24 97.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.45 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.48 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 37.0 t70 -51.91 178.87 0.01 OUTLIER 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.04 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.48 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 3.6 tp10 75.07 111.55 0.03 OUTLIER Pre-proline 0 CA--C 1.544 0.715 0 C-N-CA 120.918 -0.313 . . . . 0.0 110.874 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -72.45 155.54 55.17 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 120.874 1.049 . . . . 0.0 111.79 179.156 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 62.6 pttt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.254 179.239 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.56 -174.12 43.65 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.934 -0.867 . . . . 0.0 110.934 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 153.31 -8.81 0.49 Allowed Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 97.9 mt -63.16 -44.04 99.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.017 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 41.4 t -71.57 131.75 43.69 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.909 179.226 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 tt -66.0 -39.77 85.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.336 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.2 m95 -58.72 -28.42 65.82 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.182 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 68.9 tp60 -62.82 -31.36 72.34 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.259 -0.576 . . . . 0.0 109.717 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.7 mt -70.77 -38.34 73.43 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.163 -0.615 . . . . 0.0 110.414 178.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.418 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.2 mt -62.34 -48.18 80.96 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 111.933 0.346 . . . . 0.0 111.933 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.497 HG23 ' N ' ' A' ' 12' ' ' ILE . 20.0 tt -65.52 -42.95 94.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.158 -178.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.497 ' N ' HG23 ' A' ' 11' ' ' ILE . 77.8 mt -64.54 -43.4 96.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.518 179.477 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.69 -42.23 99.53 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.797 0.332 . . . . 0.0 110.458 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 10' ' ' LEU . 45.0 t -62.39 -45.54 98.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.202 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 74.3 mt -61.79 -45.46 98.65 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.644 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.806 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.1 t -58.48 -44.22 88.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.49 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.529 ' O ' ' N ' ' A' ' 21' ' ' GLY . 75.5 t -63.72 -43.33 97.99 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.202 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 18' ' ' LEU . 35.7 mt -63.13 -48.31 79.07 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.922 -178.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.8 mt -64.35 -41.89 96.51 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.757 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 21' ' ' GLY . 45.6 m-85 -88.35 -12.01 44.61 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.13 162.23 0.02 OUTLIER Glycine 0 CA--C 1.542 1.748 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -69.46 -25.52 29.89 Favored 'Trans proline' 0 N--CA 1.503 2.03 0 C-N-CA 121.505 1.47 . . . . 0.0 114.74 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.67 -50.59 62.41 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 120.324 -0.551 . . . . 0.0 112.366 -178.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 31.8 mmtp -67.07 -45.3 77.73 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.387 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.4 tt -61.46 -29.63 70.08 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.732 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.87 -50.98 49.82 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 28.2 m -66.49 -40.92 89.56 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.897 179.546 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.5 mt -64.72 -47.53 88.34 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.687 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.23 -51.21 56.72 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.1 m -60.59 -40.4 91.61 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.883 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -63.22 -45.25 92.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.848 0.356 . . . . 0.0 110.161 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.2 mt -79.1 -14.9 58.86 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.601 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -82.3 3.67 80.47 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -68.7 -39.2 80.6 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.887 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 39.0 t -65.6 -43.0 90.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.905 0.383 . . . . 0.0 110.584 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 87.6 mt -62.55 -41.38 91.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.751 -0.658 . . . . 0.0 109.987 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -56.37 -39.46 72.97 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.035 -178.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.02 -41.0 88.46 Favored Glycine 0 CA--C 1.52 0.389 0 C-N-CA 120.547 -0.835 . . . . 0.0 111.088 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -62.0 -47.13 86.15 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.602 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -63.91 -46.47 84.65 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.314 -0.555 . . . . 0.0 110.798 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -59.74 -50.31 74.31 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.759 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.69 -44.46 77.38 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.166 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 2.8 tpp -77.01 12.84 1.23 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 121.021 -0.271 . . . . 0.0 110.865 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 13.2 t -82.39 50.0 1.54 Allowed 'General case' 0 C--O 1.232 0.184 0 CA-C-O 120.692 0.282 . . . . 0.0 110.302 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -62.51 -40.97 98.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.566 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.472 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 38.9 t70 -150.1 178.83 8.59 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.921 -0.312 . . . . 0.0 110.177 179.487 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.472 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 26.2 tt0 -162.83 87.67 1.34 Allowed Pre-proline 0 CA--C 1.537 0.463 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.36 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -76.5 158.37 36.3 Favored 'Trans proline' 0 N--CA 1.492 1.432 0 C-N-CA 121.215 1.277 . . . . 0.0 111.703 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 98.9 mttt . . . . . 0 C--N 1.333 -0.133 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.011 179.517 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' FME . . . . . 0.541 ' SD ' ' CN ' ' A' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -87.1 120.34 5.47 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -94.41 9.99 71.45 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 97.1 mt -63.19 -43.73 98.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.707 -0.397 . . . . 0.0 109.94 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.1 t -66.88 134.16 51.5 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.208 179.241 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.2 tt -65.34 -41.2 90.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.018 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.1 m95 -59.92 -31.32 69.72 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.178 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 41.7 mm-40 -64.99 -38.48 91.1 Favored 'General case' 0 C--O 1.22 -0.455 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.659 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 60.8 mt -71.68 -34.57 69.8 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.438 178.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -61.86 -47.13 86.4 Favored 'General case' 0 C--O 1.233 0.237 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 -177.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.468 HG23 ' N ' ' A' ' 12' ' ' ILE . 17.6 tt -65.21 -42.04 93.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.21 -178.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.468 ' N ' HG23 ' A' ' 11' ' ' ILE . 84.9 mt -64.15 -42.89 96.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.461 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.2 -40.7 94.93 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.784 0.326 . . . . 0.0 110.546 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.4 t -64.03 -43.27 97.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.071 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.471 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 77.8 mt -61.04 -43.93 97.2 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.744 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.39 -44.31 84.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.377 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.1 t -63.44 -43.56 98.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.119 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.9 mt -62.83 -48.63 78.25 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.75 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.1 mt -63.9 -42.78 97.36 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.666 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.416 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.1 m-85 -86.19 -13.69 46.22 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.622 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 55.87 163.2 0.02 OUTLIER Glycine 0 CA--C 1.541 1.687 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -70.14 -19.62 34.07 Favored 'Trans proline' 0 N--CA 1.501 1.936 0 C-N-CA 121.584 1.523 . . . . 0.0 114.583 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -67.8 -52.23 39.46 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 120.292 -0.563 . . . . 0.0 112.283 -179.269 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -67.58 -44.1 78.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.209 0.528 . . . . 0.0 110.398 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.6 tt -60.97 -26.45 67.56 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.668 -179.04 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -64.95 -48.94 65.68 Favored Glycine 0 C--N 1.332 0.356 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.7 p -63.34 -40.51 97.49 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 121.004 -0.278 . . . . 0.0 110.932 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 95.2 mt -63.51 -47.67 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.712 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.59 -51.73 56.87 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.9 m -59.82 -35.24 74.29 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.988 -0.285 . . . . 0.0 110.618 -179.646 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -62.62 -44.07 97.21 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.804 -0.359 . . . . 0.0 110.101 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.2 mt -80.03 -16.35 55.29 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.516 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.04 -26.16 65.3 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.65 -38.24 90.34 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.691 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.1 m -70.69 -39.75 73.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.998 0.428 . . . . 0.0 110.706 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.2 mt -63.92 -41.62 93.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.963 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -56.28 -40.12 73.76 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.971 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.18 -43.8 88.54 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.541 -0.837 . . . . 0.0 111.023 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -62.16 -47.41 84.66 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 179.186 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -59.57 -45.7 91.09 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.339 -0.545 . . . . 0.0 110.692 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.3 tttp -62.62 -51.72 66.17 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.708 -179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -59.9 -45.24 93.18 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.36 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.435 ' O ' ' C ' ' A' ' 44' ' ' SER . 15.1 mtp -75.58 -8.8 57.68 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.769 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 43' ' ' MET . 19.8 m 36.14 75.07 0.06 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.527 0.203 . . . . 0.0 110.871 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.516 ' CG ' ' H ' ' A' ' 46' ' ' ASP . 12.3 p-10 -56.01 -66.3 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.315 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.516 ' H ' ' CG ' ' A' ' 45' ' ' ASP . 98.9 m-20 -140.98 139.78 34.27 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.194 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -156.27 147.66 16.83 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.724 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -65.28 -22.23 60.71 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 120.962 1.108 . . . . 0.0 111.826 179.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 61.6 pttt . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.276 -179.372 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' FME . . . . . 0.455 ' O1 ' ' N ' ' A' ' 2' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.455 ' N ' ' O1 ' ' A' ' 1' ' ' FME . . . 81.24 11.61 83.26 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -61.42 -41.45 99.54 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 89.4 mt -112.24 127.47 69.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.858 0.361 . . . . 0.0 110.389 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.1 t -64.13 130.32 43.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.257 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.9 tt -65.34 -40.1 87.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.178 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.0 m95 -58.11 -29.44 65.5 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.904 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -63.01 -31.73 72.94 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.942 -0.703 . . . . 0.0 109.771 179.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.7 -39.1 73.66 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.383 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.435 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.5 mt -61.63 -48.22 81.86 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 111.825 0.306 . . . . 0.0 111.825 -179.025 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.458 HG23 ' N ' ' A' ' 12' ' ' ILE . 19.6 tt -66.0 -43.34 92.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.201 -0.599 . . . . 0.0 110.169 -179.304 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.458 ' N ' HG23 ' A' ' 11' ' ' ILE . 86.3 mt -64.17 -43.44 97.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.611 179.551 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.43 -40.53 94.8 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.599 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 10' ' ' LEU . 44.8 t -63.52 -45.32 98.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.784 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.473 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 79.9 mt -61.92 -44.62 99.13 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 C-N-CA 120.172 -0.611 . . . . 0.0 110.854 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 69.0 t -59.19 -44.59 92.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.401 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.6 t -63.44 -44.07 98.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.192 -179.65 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.2 mt -62.39 -48.57 79.14 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.576 -0.45 . . . . 0.0 112.156 -178.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.473 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 47.9 mt -63.91 -40.79 97.3 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.965 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -90.06 -13.73 35.29 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 121.202 -0.199 . . . . 0.0 111.51 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.33 163.36 0.04 OUTLIER Glycine 0 CA--C 1.532 1.124 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -68.79 -25.19 33.66 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.107 1.204 . . . . 0.0 114.443 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 tptp -67.19 -50.34 61.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.038 -0.665 . . . . 0.0 112.599 -178.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.6 mmtt -66.98 -45.44 77.65 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.343 -178.693 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 10.0 tt -62.35 -30.76 71.4 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.415 -179.1 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.85 -51.6 44.89 Favored Glycine 0 C--N 1.334 0.439 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.346 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 58.5 p -66.92 -41.54 86.89 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.01 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 94.6 mt -64.71 -47.91 86.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.921 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.86 -50.92 57.78 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 120.453 -0.879 . . . . 0.0 110.994 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p -60.71 -42.64 97.62 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.937 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -63.61 -45.42 90.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.891 0.377 . . . . 0.0 110.042 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.1 mt -79.26 -16.53 56.3 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.594 179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -87.18 5.65 84.75 Favored Glycine 0 CA--C 1.532 1.095 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.15 -38.19 78.63 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.122 0.461 . . . . 0.0 110.805 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 19.5 m -65.6 -43.51 89.43 Favored 'General case' 0 C--O 1.227 -0.123 0 CA-C-O 120.98 0.419 . . . . 0.0 110.7 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.3 mt -63.38 -41.92 94.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.116 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -57.6 -39.97 78.03 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.014 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.52 -41.14 90.7 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -61.3 -46.98 88.06 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.806 -0.358 . . . . 0.0 110.11 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -63.14 -45.48 91.71 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.703 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' ' O ' ' A' ' 44' ' ' SER . 4.4 tmtt? -61.94 -51.43 68.12 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.298 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.72 -46.13 77.78 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.443 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 2.7 mpp? -79.25 13.66 1.79 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 120.851 -0.34 . . . . 0.0 111.056 179.537 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 41' ' ' LYS . 40.0 t -137.97 144.86 41.37 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.458 ' OD1' ' N ' ' A' ' 45' ' ' ASP . 20.0 p-10 -88.32 -56.77 3.18 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 121.172 -0.211 . . . . 0.0 110.47 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.0 178.01 9.88 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 121.091 -0.244 . . . . 0.0 110.442 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -171.07 92.78 0.44 Allowed Pre-proline 0 CA--C 1.538 0.511 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.856 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -54.54 -34.91 84.22 Favored 'Trans proline' 0 N--CA 1.494 1.518 0 C-N-CA 120.799 0.999 . . . . 0.0 111.803 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 99.5 mttt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.763 -179.745 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.74 168.06 41.92 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 61.48 38.19 95.37 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 86.0 mt -47.66 -90.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.2 p -78.59 168.23 20.08 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.4 tt -63.17 -37.97 80.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.025 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 3.6 m95 -57.96 -28.82 64.67 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.917 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -63.39 -31.91 73.2 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.443 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.0 mt -71.53 -37.71 71.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.142 -0.623 . . . . 0.0 110.464 179.13 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.474 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.6 mt -62.23 -47.48 84.23 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -178.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.487 HG23 ' N ' ' A' ' 12' ' ' ILE . 20.6 tt -67.19 -42.91 88.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.227 -179.334 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.487 ' N ' HG23 ' A' ' 11' ' ' ILE . 94.9 mt -63.68 -43.45 98.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.312 179.398 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.0 -38.64 83.2 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.891 0.377 . . . . 0.0 110.432 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 10' ' ' LEU . 42.8 t -61.76 -42.94 96.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.079 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.458 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.1 mt -60.77 -43.93 96.33 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.568 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.689 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 44.9 t -57.88 -43.98 85.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.387 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.496 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.6 t -63.18 -43.44 98.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.086 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.0 mt -62.82 -48.54 78.65 Favored 'General case' 0 C--N 1.33 -0.26 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.751 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.458 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.3 mt -64.01 -42.06 97.26 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.667 -179.074 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' A' ' 21' ' ' GLY . 38.9 m-85 -85.47 -12.99 50.5 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 121.143 -0.223 . . . . 0.0 111.595 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.62 159.12 0.01 OUTLIER Glycine 0 CA--C 1.54 1.641 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -70.24 -22.5 29.78 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.465 1.444 . . . . 0.0 114.625 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -67.73 -52.33 38.79 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 120.449 -0.501 . . . . 0.0 112.256 -179.07 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 42.5 tttp -66.29 -44.61 83.03 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 120.447 -0.501 . . . . 0.0 110.443 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt -62.91 -25.69 68.44 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.653 -179.11 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.02 -50.38 58.05 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -65.85 -39.31 90.65 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.892 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.69 -47.76 89.7 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.723 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -61.62 -50.77 62.9 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.0 m -59.69 -37.57 79.2 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 121.03 -0.268 . . . . 0.0 110.672 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -63.36 -44.91 93.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.933 0.397 . . . . 0.0 110.092 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.8 mt -81.22 -18.8 44.85 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.579 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -66.11 -10.72 53.04 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -67.9 -38.3 82.79 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.693 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.9 m -68.17 -39.54 82.52 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.096 0.474 . . . . 0.0 110.517 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 89.9 mt -63.95 -41.75 93.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.103 179.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -56.57 -41.97 77.81 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.231 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.92 -43.12 84.0 Favored Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.512 -0.851 . . . . 0.0 110.998 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -62.3 -46.68 87.67 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 38.5 ttmt -62.17 -45.35 93.81 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.433 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 30.9 ttpt -60.31 -51.62 68.75 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.724 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.18 -44.03 87.81 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 119.574 -0.851 . . . . 0.0 111.21 179.621 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 24.4 mtm -77.6 12.77 1.49 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 121.089 -0.244 . . . . 0.0 110.844 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 97.0 p -71.02 -17.74 62.61 Favored 'General case' 0 CA--C 1.526 0.049 0 CA-C-O 120.816 0.341 . . . . 0.0 110.557 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -62.21 -42.23 99.11 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.337 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -135.52 66.07 1.53 Allowed 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -168.88 90.63 0.6 Allowed Pre-proline 0 CA--C 1.538 0.481 0 C-N-CA 120.355 -0.538 . . . . 0.0 110.848 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -54.79 -38.93 91.82 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 120.917 1.078 . . . . 0.0 111.836 179.472 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 64.5 tttm . . . . . 0 C--N 1.332 -0.193 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.362 -179.89 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -69.1 149.12 48.69 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.07 35.17 0.72 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.949 -0.861 . . . . 0.0 110.949 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 86.0 mt -62.57 -43.98 98.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.9 t -96.41 123.28 40.0 Favored 'General case' 0 N--CA 1.463 0.195 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.069 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 tt -66.35 -40.4 86.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.278 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 3.3 m95 -58.39 -28.44 65.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.209 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 64.4 tp60 -63.68 -32.0 73.35 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 120.229 -0.588 . . . . 0.0 109.545 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 95.9 mt -70.89 -38.51 73.03 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 119.955 -0.698 . . . . 0.0 110.509 179.092 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.424 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.6 mt -62.12 -47.91 82.49 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -178.485 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.474 HG23 ' N ' ' A' ' 12' ' ' ILE . 19.7 tt -66.01 -42.69 92.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 C-N-CA 120.356 -0.538 . . . . 0.0 110.181 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.474 ' N ' HG23 ' A' ' 11' ' ' ILE . 83.2 mt -64.28 -43.78 97.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 120.671 -0.412 . . . . 0.0 110.598 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.23 -40.6 94.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.456 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 10' ' ' LEU . 43.0 t -62.47 -44.17 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.067 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.475 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.6 mt -61.87 -44.96 99.59 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.612 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.936 -179.35 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 52.1 t -58.84 -44.22 90.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.473 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' GLY . 73.5 t -63.63 -43.38 98.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.71 -0.396 . . . . 0.0 111.249 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 18' ' ' LEU . 37.2 mt -63.16 -48.47 78.3 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.98 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 42.3 mt -64.19 -41.02 97.26 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.872 -179.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 21' ' ' GLY . 44.7 m-85 -88.89 -12.28 42.21 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 111.609 0.226 . . . . 0.0 111.609 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.42 161.26 0.02 OUTLIER Glycine 0 CA--C 1.54 1.63 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.25 -24.96 26.85 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 121.466 1.444 . . . . 0.0 114.718 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.76 -51.18 58.83 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 120.398 -0.521 . . . . 0.0 112.371 -178.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -67.28 -45.02 77.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt -61.0 -29.1 69.5 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.716 -178.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.03 -50.72 56.36 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -65.26 -40.85 94.52 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.839 -0.344 . . . . 0.0 110.858 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.61 -47.57 90.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.668 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.529 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.05 -49.9 67.93 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.7 t -59.54 -43.1 93.59 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 121.039 -0.265 . . . . 0.0 110.585 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -62.03 -45.47 93.45 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.096 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.4 mt -79.18 -21.54 46.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.682 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -81.85 -0.24 89.18 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.565 -0.614 . . . . 0.0 111.565 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.97 -38.36 85.94 Favored 'General case' 0 CA--C 1.527 0.072 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.857 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 38.3 t -65.21 -40.51 94.24 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.091 0.472 . . . . 0.0 110.54 179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.9 mt -61.81 -41.2 89.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.995 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -57.37 -41.32 79.92 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.057 -179.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.01 -38.87 94.5 Favored Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.592 -0.813 . . . . 0.0 111.106 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.456 ' O ' ' CE ' ' A' ' 43' ' ' MET . 5.5 m-85 -62.13 -47.67 83.56 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -64.98 -46.5 81.19 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.771 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -58.88 -49.02 79.33 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 120.51 -0.476 . . . . 0.0 110.942 -179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.96 -46.79 75.06 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 119.49 -0.884 . . . . 0.0 111.144 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.456 ' CE ' ' O ' ' A' ' 39' ' ' PHE . 3.4 mpp? -78.23 12.94 1.66 Allowed 'General case' 0 CA--C 1.534 0.342 0 O-C-N 122.209 -0.307 . . . . 0.0 110.787 179.386 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 22.7 t -144.32 43.05 1.41 Allowed 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 120.756 0.312 . . . . 0.0 110.418 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -61.77 -44.69 96.39 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.777 -0.369 . . . . 0.0 110.451 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.522 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 38.0 t70 -82.19 -178.2 6.93 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.555 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.54 ' N ' ' CD ' ' A' ' 47' ' ' GLU . 1.2 pm0 -153.32 79.6 5.48 Favored Pre-proline 0 CA--C 1.536 0.437 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.126 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -74.66 155.8 44.57 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 120.942 1.094 . . . . 0.0 112.011 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 65.1 tttm . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.218 179.395 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.08 0 CA-C-O 120.715 0.293 . . . . 0.0 110.415 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -62.55 -43.6 98.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.083 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.497 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -62.32 -44.46 99.2 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.68 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.768 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 45.1 t -58.9 -45.21 91.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.428 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.4 t -62.62 -43.43 98.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.218 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.0 mt -63.29 -48.16 79.29 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.989 -178.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.497 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.1 mt -63.96 -41.69 97.5 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.504 -0.479 . . . . 0.0 110.767 -178.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -87.93 -12.77 43.66 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.58 161.5 0.03 OUTLIER Glycine 0 CA--C 1.54 1.636 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -70.0 -25.13 27.78 Favored 'Trans proline' 0 N--CA 1.502 1.994 0 C-N-CA 121.5 1.467 . . . . 0.0 114.572 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -66.72 -50.7 61.95 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.342 -0.543 . . . . 0.0 112.416 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -67.3 -44.97 77.89 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.534 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt . . . . . 0 C--N 1.324 -0.525 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.773 -179.128 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.764 0.316 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 52.9 t -63.71 -44.09 98.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.088 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 78.9 mt -61.53 -44.54 98.78 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.732 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.5 t -57.7 -43.77 84.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 C-N-CA 120.29 -0.564 . . . . 0.0 110.344 -179.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.8 t -63.86 -43.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.186 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 36.0 mt -62.73 -49.13 76.25 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.811 -178.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.47 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 36.3 mt -62.73 -42.33 99.61 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.326 -0.55 . . . . 0.0 110.626 -178.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -87.23 -14.1 42.01 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 121.062 -0.255 . . . . 0.0 111.676 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.54 161.96 0.04 OUTLIER Glycine 0 CA--C 1.543 1.807 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -68.87 -20.9 38.58 Favored 'Trans proline' 0 N--CA 1.504 2.141 0 C-N-CA 121.58 1.52 . . . . 0.0 114.772 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -69.21 -50.86 43.46 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -67.66 -47.09 70.52 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.355 -0.538 . . . . 0.0 110.477 -179.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt . . . . . 0 C--N 1.324 -0.531 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.702 -179.174 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.852 0.358 . . . . 0.0 110.389 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.6 t -60.75 -43.01 94.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.03 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -59.8 -43.37 91.65 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.592 0 C-N-CA 120.167 -0.613 . . . . 0.0 110.698 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.0 t -57.0 -43.84 81.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.386 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.6 t -61.99 -44.07 98.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.194 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.1 mt -62.76 -48.0 81.06 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.757 -178.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.474 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 29.1 mt -63.88 -41.69 97.68 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.613 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' A' ' 21' ' ' GLY . 40.5 m-85 -86.81 -13.07 46.15 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 111.57 0.211 . . . . 0.0 111.57 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.13 160.28 0.02 OUTLIER Glycine 0 CA--C 1.54 1.631 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.76 -16.27 33.36 Favored 'Trans proline' 0 N--CA 1.502 2.029 0 C-N-CA 121.502 1.468 . . . . 0.0 114.507 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.0 ttpt -67.48 -52.72 35.97 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -68.56 -47.54 66.58 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.533 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--N 1.325 -0.497 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.581 -179.185 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.761 0.315 . . . . 0.0 110.351 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.8 t -62.51 -44.14 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.026 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.482 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.7 mt -61.58 -44.77 99.19 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.75 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.5 t -58.79 -44.44 90.31 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.528 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.2 t -63.15 -43.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.229 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.9 mt -62.95 -48.23 79.79 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.944 -178.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -64.11 -40.55 96.46 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.87 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -88.69 -14.65 36.81 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 111.637 0.236 . . . . 0.0 111.637 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 60.76 160.54 0.09 OUTLIER Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -70.28 -27.66 23.7 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.461 1.441 . . . . 0.0 114.666 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -65.84 -49.78 66.95 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -67.12 -44.99 78.52 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.434 -179.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.1 tt . . . . . 0 C--N 1.324 -0.516 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.78 -179.174 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.14 0 CA-C-O 120.842 0.354 . . . . 0.0 110.307 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 40.4 t -60.83 -43.1 94.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.944 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.463 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.4 mt -60.67 -44.04 96.2 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.533 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.751 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.8 t -57.67 -44.32 85.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.389 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.0 t -62.71 -43.81 98.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.238 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.406 HD23 ' HA ' ' A' ' 18' ' ' LEU . 35.3 mt -62.69 -48.12 80.67 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.729 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -63.6 -42.05 98.27 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.467 -0.493 . . . . 0.0 110.757 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.9 m-85 -86.77 -12.07 49.18 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.509 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.18 160.21 0.01 OUTLIER Glycine 0 CA--C 1.543 1.806 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -72.82 -12.73 26.55 Favored 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 121.434 1.423 . . . . 0.0 114.544 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.52 -55.13 12.73 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 120.301 -0.559 . . . . 0.0 112.338 -179.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -68.82 -46.9 67.42 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.175 0.512 . . . . 0.0 110.584 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.455 HD23 ' O ' ' A' ' 25' ' ' LEU . 8.8 tt . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.68 -178.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.797 0.332 . . . . 0.0 110.458 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.0 t -62.39 -45.54 98.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.202 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 74.3 mt -61.79 -45.46 98.65 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.644 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.806 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.1 t -58.48 -44.22 88.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.49 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.529 ' O ' ' N ' ' A' ' 21' ' ' GLY . 75.5 t -63.72 -43.33 97.99 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.202 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 18' ' ' LEU . 35.7 mt -63.13 -48.31 79.07 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.922 -178.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.8 mt -64.35 -41.89 96.51 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.757 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 21' ' ' GLY . 45.6 m-85 -88.35 -12.01 44.61 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.13 162.23 0.02 OUTLIER Glycine 0 CA--C 1.542 1.748 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -69.46 -25.52 29.89 Favored 'Trans proline' 0 N--CA 1.503 2.03 0 C-N-CA 121.505 1.47 . . . . 0.0 114.74 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.67 -50.59 62.41 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 120.324 -0.551 . . . . 0.0 112.366 -178.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 31.8 mmtp -67.07 -45.3 77.73 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.387 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.4 tt . . . . . 0 C--N 1.324 -0.507 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.732 -179.232 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.784 0.326 . . . . 0.0 110.546 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.4 t -64.03 -43.27 97.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.071 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.471 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 77.8 mt -61.04 -43.93 97.2 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.744 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.39 -44.31 84.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.377 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.1 t -63.44 -43.56 98.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.119 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.9 mt -62.83 -48.63 78.25 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.75 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.1 mt -63.9 -42.78 97.36 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.666 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.416 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.1 m-85 -86.19 -13.69 46.22 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.622 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 55.87 163.2 0.02 OUTLIER Glycine 0 CA--C 1.541 1.687 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -70.14 -19.62 34.07 Favored 'Trans proline' 0 N--CA 1.501 1.936 0 C-N-CA 121.584 1.523 . . . . 0.0 114.583 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -67.8 -52.23 39.46 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 120.292 -0.563 . . . . 0.0 112.283 -179.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -67.58 -44.1 78.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.209 0.528 . . . . 0.0 110.398 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.6 tt . . . . . 0 C--N 1.327 -0.402 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.668 -179.04 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.164 0 CA-C-O 120.745 0.307 . . . . 0.0 110.599 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.8 t -63.52 -45.32 98.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.784 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.473 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 79.9 mt -61.92 -44.62 99.13 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 C-N-CA 120.172 -0.611 . . . . 0.0 110.854 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 69.0 t -59.19 -44.59 92.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.401 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.6 t -63.44 -44.07 98.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.192 -179.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.2 mt -62.39 -48.57 79.14 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.576 -0.45 . . . . 0.0 112.156 -178.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.473 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 47.9 mt -63.91 -40.79 97.3 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.965 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -90.06 -13.73 35.29 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 121.202 -0.199 . . . . 0.0 111.51 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.33 163.36 0.04 OUTLIER Glycine 0 CA--C 1.532 1.124 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -68.79 -25.19 33.66 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.107 1.204 . . . . 0.0 114.443 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 tptp -67.19 -50.34 61.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.038 -0.665 . . . . 0.0 112.599 -178.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.6 mmtt -66.98 -45.44 77.65 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.343 -178.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 10.0 tt . . . . . 0 C--N 1.324 -0.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.415 -179.1 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.891 0.377 . . . . 0.0 110.432 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.76 -42.94 96.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.079 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.458 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.1 mt -60.77 -43.93 96.33 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.568 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.689 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 44.9 t -57.88 -43.98 85.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.387 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.496 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.6 t -63.18 -43.44 98.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.086 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.0 mt -62.82 -48.54 78.65 Favored 'General case' 0 C--N 1.33 -0.26 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.751 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.458 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.3 mt -64.01 -42.06 97.26 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.667 -179.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' A' ' 21' ' ' GLY . 38.9 m-85 -85.47 -12.99 50.5 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 121.143 -0.223 . . . . 0.0 111.595 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.62 159.12 0.01 OUTLIER Glycine 0 CA--C 1.54 1.641 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -70.24 -22.5 29.78 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.465 1.444 . . . . 0.0 114.625 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -67.73 -52.33 38.79 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 120.449 -0.501 . . . . 0.0 112.256 -179.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 42.5 tttp -66.29 -44.61 83.03 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 120.447 -0.501 . . . . 0.0 110.443 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt . . . . . 0 C--N 1.324 -0.538 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.653 -179.11 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.121 0 CA-C-O 120.814 0.34 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 43.0 t -62.47 -44.17 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.067 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.475 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.6 mt -61.87 -44.96 99.59 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.612 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.936 -179.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 52.1 t -58.84 -44.22 90.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.473 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' GLY . 73.5 t -63.63 -43.38 98.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.71 -0.396 . . . . 0.0 111.249 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 18' ' ' LEU . 37.2 mt -63.16 -48.47 78.3 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.98 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 42.3 mt -64.19 -41.02 97.26 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.872 -179.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 21' ' ' GLY . 44.7 m-85 -88.89 -12.28 42.21 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 111.609 0.226 . . . . 0.0 111.609 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.42 161.26 0.02 OUTLIER Glycine 0 CA--C 1.54 1.63 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.25 -24.96 26.85 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 121.466 1.444 . . . . 0.0 114.718 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.76 -51.18 58.83 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 120.398 -0.521 . . . . 0.0 112.371 -178.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -67.28 -45.02 77.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt . . . . . 0 C--N 1.324 -0.506 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.716 -178.948 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.27 -36.64 93.47 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 153.47 19.72 0.05 OUTLIER Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 74.4 mt -64.65 -25.05 36.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.055 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.2 t -65.06 130.4 43.21 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.107 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.3 tt -65.15 -40.67 89.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.1 -179.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -58.84 -31.68 68.73 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.161 179.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -64.23 -38.38 90.83 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.252 -0.579 . . . . 0.0 109.74 179.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 69.2 mt -70.62 -36.26 73.39 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.184 -0.607 . . . . 0.0 110.587 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.402 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.2 tt -62.43 -48.27 80.43 Favored 'General case' 0 C--O 1.23 0.067 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -178.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.464 HG23 ' N ' ' A' ' 12' ' ' ILE . 20.0 tt -67.05 -42.17 88.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.024 -178.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.464 ' N ' HG23 ' A' ' 11' ' ' ILE . 95.1 mt -63.52 -43.48 98.34 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.134 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.24 179.519 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.29 -39.2 82.21 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.415 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.0 t -62.55 -43.6 98.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.083 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.497 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -62.32 -44.46 99.2 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.68 0 C-N-CA 120.23 -0.588 . . . . 0.0 110.768 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 45.1 t -58.9 -45.21 91.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.428 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.4 t -62.62 -43.43 98.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.218 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.0 mt -63.29 -48.16 79.29 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.438 -0.505 . . . . 0.0 111.989 -178.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.497 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.1 mt -63.96 -41.69 97.5 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 120.504 -0.479 . . . . 0.0 110.767 -178.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.4 m-85 -87.93 -12.77 43.66 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.58 161.5 0.03 OUTLIER Glycine 0 CA--C 1.54 1.636 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -70.0 -25.13 27.78 Favored 'Trans proline' 0 N--CA 1.502 1.994 0 C-N-CA 121.5 1.467 . . . . 0.0 114.572 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -66.72 -50.7 61.95 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.342 -0.543 . . . . 0.0 112.416 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -67.3 -44.97 77.89 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.534 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt -61.56 -29.85 70.28 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.773 -179.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.98 -51.06 48.48 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.0 p -66.13 -41.36 90.57 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.876 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 92.7 mt -64.61 -46.91 91.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.703 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.77 -51.05 56.92 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.6 t -60.28 -42.03 94.58 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.981 -0.288 . . . . 0.0 110.734 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -62.36 -45.36 93.53 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.014 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 74.8 mt -80.51 -20.25 44.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.559 179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -82.93 1.15 89.08 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -67.13 -35.73 80.37 Favored 'General case' 0 C--O 1.231 0.115 0 O-C-N 122.566 -0.373 . . . . 0.0 110.903 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.9 p -67.72 -37.97 82.95 Favored 'General case' 0 C--O 1.224 -0.271 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.526 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 88.8 mt -62.48 -41.16 90.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.037 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -56.66 -38.13 71.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.025 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.95 -38.19 92.67 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -61.99 -45.59 92.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.878 0.371 . . . . 0.0 110.037 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.0 tttp -64.53 -46.08 84.42 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.525 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -59.38 -50.41 74.05 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 120.608 -0.437 . . . . 0.0 110.607 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.96 -43.59 77.64 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.958 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 37.3 mtm -75.75 0.88 16.34 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 120.994 -0.283 . . . . 0.0 110.593 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 59.2 p -67.91 -38.02 82.43 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.815 0.341 . . . . 0.0 110.58 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -63.11 -41.74 99.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.367 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.489 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 38.8 t70 -78.21 177.35 8.46 Favored 'General case' 0 C--O 1.232 0.146 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.628 ' N ' ' OE2' ' A' ' 47' ' ' GLU . 0.8 OUTLIER -153.62 80.91 5.0 Favored Pre-proline 0 CA--C 1.536 0.42 0 C-N-CA 120.803 -0.359 . . . . 0.0 111.6 179.958 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -53.23 -36.9 79.52 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 120.808 1.005 . . . . 0.0 111.718 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 20.9 ptmt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.089 -179.843 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.53 62.98 3.76 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -155.53 147.56 16.58 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.868 -0.893 . . . . 0.0 110.868 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 78.5 mt -107.21 123.77 62.62 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.079 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.5 t -74.58 128.63 36.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.994 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.3 tt -65.96 -40.42 87.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.938 0.399 . . . . 0.0 110.215 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 3.6 m95 -60.81 -30.02 69.82 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.294 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.401 ' O ' HG22 ' A' ' 11' ' ' ILE . 25.3 mm-40 -63.16 -34.76 78.33 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.213 -0.595 . . . . 0.0 109.788 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 66.3 mt -71.62 -35.06 70.33 Favored 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.074 -0.65 . . . . 0.0 110.594 179.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.406 ' O ' HG23 ' A' ' 14' ' ' VAL . 3.2 mt -62.18 -46.29 89.62 Favored 'General case' 0 CA--C 1.526 0.046 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -178.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.481 HG23 ' N ' ' A' ' 12' ' ' ILE . 16.9 tt -64.82 -42.97 96.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.994 -178.565 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.481 ' N ' HG23 ' A' ' 11' ' ' ILE . 81.2 mt -64.73 -42.91 96.3 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.385 179.681 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.9 -41.1 97.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.764 0.316 . . . . 0.0 110.424 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 10' ' ' LEU . 52.9 t -63.71 -44.09 98.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.088 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 78.9 mt -61.53 -44.54 98.78 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 C-N-CA 120.145 -0.622 . . . . 0.0 110.732 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.5 t -57.7 -43.77 84.36 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 C-N-CA 120.29 -0.564 . . . . 0.0 110.344 -179.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.539 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.8 t -63.86 -43.8 97.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.186 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 36.0 mt -62.73 -49.13 76.25 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.811 -178.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.47 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 36.3 mt -62.73 -42.33 99.61 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.326 -0.55 . . . . 0.0 110.626 -178.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.0 m-85 -87.23 -14.1 42.01 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 121.062 -0.255 . . . . 0.0 111.676 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.54 161.96 0.04 OUTLIER Glycine 0 CA--C 1.543 1.807 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -68.87 -20.9 38.58 Favored 'Trans proline' 0 N--CA 1.504 2.141 0 C-N-CA 121.58 1.52 . . . . 0.0 114.772 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -69.21 -50.86 43.46 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -67.66 -47.09 70.52 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.355 -0.538 . . . . 0.0 110.477 -179.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt -61.21 -27.8 68.69 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.702 -179.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.12 -50.81 55.41 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 46.2 t -65.53 -41.08 93.5 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.713 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.88 -47.07 92.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.187 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.849 -179.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.524 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.38 -51.22 56.35 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 72.5 p -59.86 -42.03 92.78 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 121.009 -0.276 . . . . 0.0 110.828 -179.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -61.27 -45.75 93.2 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.093 179.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.9 mt -80.34 -19.84 45.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.707 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -74.84 -1.52 62.53 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 -179.508 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.25 -34.55 78.36 Favored 'General case' 0 C--N 1.332 -0.175 0 C-N-CA 120.769 -0.373 . . . . 0.0 110.522 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.7 m -65.37 -34.01 77.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.022 0.439 . . . . 0.0 110.563 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.6 mt -61.84 -40.78 88.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.949 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -56.94 -41.65 78.62 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.076 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.21 -37.67 93.16 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -62.3 -45.78 91.72 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -63.06 -46.26 88.31 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.435 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -58.91 -51.29 70.69 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 120.421 -0.512 . . . . 0.0 110.561 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.45 -44.27 80.32 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.136 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 16.8 mtm -77.06 12.5 1.39 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 121.133 -0.227 . . . . 0.0 110.622 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 60.5 p -133.01 4.93 3.83 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 120.888 0.375 . . . . 0.0 110.771 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -127.95 -75.65 0.57 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.41 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.497 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 37.7 t70 -163.15 179.25 7.6 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.071 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.497 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 7.6 mp0 -141.33 81.17 15.8 Favored Pre-proline 0 CA--C 1.54 0.577 0 C-N-CA 120.659 -0.417 . . . . 0.0 111.38 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -52.9 -38.21 78.63 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 121.031 1.154 . . . . 0.0 111.828 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 C--N 1.332 -0.158 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.225 -179.669 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.24 13.11 81.35 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 82.72 2.99 90.69 Favored Glycine 0 CA--C 1.521 0.409 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 93.4 mt -103.89 114.03 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-O 120.746 0.308 . . . . 0.0 110.342 179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.4 t -77.11 160.79 28.77 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.935 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.3 tt -64.99 -39.05 84.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.931 0.396 . . . . 0.0 110.226 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.4 m95 -58.84 -29.09 66.67 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.038 179.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -62.52 -30.5 71.33 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.181 -0.608 . . . . 0.0 109.461 179.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.403 HD23 ' HA ' ' A' ' 9' ' ' LEU . 96.7 mt -71.64 -37.86 70.8 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 120.072 -0.651 . . . . 0.0 110.627 178.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.43 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.4 mt -62.26 -47.47 84.23 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 111.959 0.355 . . . . 0.0 111.959 -178.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.476 HG23 ' N ' ' A' ' 12' ' ' ILE . 20.2 tt -65.91 -42.56 92.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.035 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.476 ' N ' HG23 ' A' ' 11' ' ' ILE . 92.6 mt -63.17 -42.85 98.06 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.151 0 C-N-CA 120.751 -0.38 . . . . 0.0 110.232 179.282 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.81 -38.17 84.5 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.852 0.358 . . . . 0.0 110.389 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 10' ' ' LEU . 39.6 t -60.75 -43.01 94.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.03 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.474 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 76.4 mt -59.8 -43.37 91.65 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.592 0 C-N-CA 120.167 -0.613 . . . . 0.0 110.698 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.0 t -57.0 -43.84 81.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.386 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.519 ' O ' ' N ' ' A' ' 21' ' ' GLY . 53.6 t -61.99 -44.07 98.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.194 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.1 mt -62.76 -48.0 81.06 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.757 -178.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.474 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 29.1 mt -63.88 -41.69 97.68 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.613 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' A' ' 21' ' ' GLY . 40.5 m-85 -86.81 -13.07 46.15 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 111.57 0.211 . . . . 0.0 111.57 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.13 160.28 0.02 OUTLIER Glycine 0 CA--C 1.54 1.631 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.76 -16.27 33.36 Favored 'Trans proline' 0 N--CA 1.502 2.029 0 C-N-CA 121.502 1.468 . . . . 0.0 114.507 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.0 ttpt -67.48 -52.72 35.97 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -68.56 -47.54 66.58 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.533 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.87 -26.69 68.9 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.581 -179.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -66.22 -51.13 46.46 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -66.98 -41.74 86.28 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.791 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.02 -47.96 88.08 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.148 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.725 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.02 -50.87 59.78 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.054 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 20.2 m -60.64 -39.94 90.11 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 121.171 -0.211 . . . . 0.0 110.893 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -63.49 -45.31 91.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.89 0.376 . . . . 0.0 110.103 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.2 mt -79.11 -14.85 58.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.59 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -82.93 3.82 82.52 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -67.4 -37.65 83.45 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.795 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 78.1 p -68.82 -38.81 80.15 Favored 'General case' 0 C--O 1.224 -0.256 0 CA-C-O 121.049 0.452 . . . . 0.0 110.703 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.2 mt -63.4 -41.61 93.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.018 179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -56.58 -42.62 78.96 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.14 -178.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.96 -41.32 97.41 Favored Glycine 0 CA--C 1.521 0.439 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.112 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -61.76 -45.75 92.56 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -64.25 -46.41 83.87 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.513 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -59.82 -50.53 73.43 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 120.599 -0.44 . . . . 0.0 110.713 -179.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.13 -42.06 76.3 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.079 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 25.1 mtm -76.53 13.6 0.95 Allowed 'General case' 0 CA--C 1.536 0.442 0 O-C-N 122.238 -0.289 . . . . 0.0 110.74 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 35.2 t -76.26 -3.95 39.33 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.686 0.279 . . . . 0.0 110.459 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -62.4 -39.9 94.75 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.458 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 45.9 t0 58.95 177.06 0.07 Allowed 'General case' 0 C--O 1.231 0.123 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -155.98 147.9 17.29 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.816 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -64.93 -23.98 61.19 Favored 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 120.99 1.127 . . . . 0.0 111.9 179.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 62.8 mttp . . . . . 0 C--N 1.332 -0.192 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.387 -179.658 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.2 -38.55 96.68 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -169.55 168.96 41.72 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 96.1 mt -85.37 126.59 40.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.9 t -84.23 128.33 34.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.198 -0.455 . . . . 0.0 109.862 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.5 tt -64.58 -40.52 89.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.168 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -58.51 -30.9 67.41 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.01 179.354 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -65.23 -37.64 87.89 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 179.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 90.4 mt -70.81 -36.96 73.2 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.122 -0.631 . . . . 0.0 110.17 178.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.424 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.8 tt -62.54 -48.42 79.6 Favored 'General case' 0 CA--C 1.527 0.092 0 N-CA-C 112.06 0.393 . . . . 0.0 112.06 -178.119 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.475 HG23 ' N ' ' A' ' 12' ' ' ILE . 19.5 tt -66.06 -42.62 91.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.052 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.475 ' N ' HG23 ' A' ' 11' ' ' ILE . 95.2 mt -63.71 -42.92 97.62 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.403 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.37 -38.62 84.48 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.351 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 10' ' ' LEU . 44.8 t -62.51 -44.14 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.026 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.482 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.7 mt -61.58 -44.77 99.19 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.75 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.5 t -58.79 -44.44 90.31 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.528 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.2 t -63.15 -43.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.229 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.9 mt -62.95 -48.23 79.79 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.944 -178.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -64.11 -40.55 96.46 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.87 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -88.69 -14.65 36.81 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 111.637 0.236 . . . . 0.0 111.637 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 60.76 160.54 0.09 OUTLIER Glycine 0 CA--C 1.54 1.605 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -70.28 -27.66 23.7 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.461 1.441 . . . . 0.0 114.666 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -65.84 -49.78 66.95 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -178.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -67.12 -44.99 78.52 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.434 -179.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.1 tt -61.37 -29.56 69.98 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.78 -179.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.46 -50.99 52.34 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 39.1 m -64.25 -40.55 96.24 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.852 179.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.6 mt -64.49 -47.61 88.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.731 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.447 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -61.83 -50.97 60.57 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 120.395 -0.907 . . . . 0.0 110.875 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 76.1 p -60.57 -39.81 89.37 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 121.054 -0.259 . . . . 0.0 110.848 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -62.24 -45.6 92.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.916 0.388 . . . . 0.0 110.155 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.4 mt -80.2 -18.19 50.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.743 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -77.49 1.31 66.51 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.38 -36.27 82.43 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.886 0.374 . . . . 0.0 110.921 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 36.5 t -66.38 -36.91 84.06 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.514 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 86.0 mt -61.73 -40.76 87.96 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.206 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -56.28 -38.87 71.78 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.036 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.34 -36.48 91.71 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -62.78 -47.01 85.34 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.019 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -63.39 -46.58 85.77 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.525 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -58.78 -50.77 72.72 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.713 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.23 -44.85 79.97 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 119.681 -0.808 . . . . 0.0 111.196 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.429 ' O ' ' O ' ' A' ' 44' ' ' SER . 34.1 ttm -77.57 13.4 1.28 Allowed 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 121.082 -0.247 . . . . 0.0 110.841 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.486 ' HG ' ' HB3' ' A' ' 47' ' ' GLU . 10.6 t 58.25 151.87 0.01 OUTLIER 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.678 0.275 . . . . 0.0 110.682 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -85.65 -89.21 0.11 Allowed 'General case' 0 CA--C 1.524 -0.028 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.422 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -97.57 48.96 1.03 Allowed 'General case' 0 C--N 1.339 0.136 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.252 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.486 ' HB3' ' HG ' ' A' ' 44' ' ' SER . 39.0 tt0 -165.3 90.15 0.94 Allowed Pre-proline 0 CA--C 1.536 0.438 0 C-N-CA 120.434 -0.507 . . . . 0.0 111.091 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -59.91 145.74 97.56 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 120.881 1.054 . . . . 0.0 111.736 179.318 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt . . . . . 0 N--CA 1.463 0.21 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.143 179.641 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . 0.564 ' N ' ' SD ' ' A' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.77 -39.09 97.1 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -83.58 -163.92 35.75 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 92.0 mt -87.07 114.96 27.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 121.004 0.43 . . . . 0.0 110.046 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.4 t -70.6 150.07 46.43 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.095 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.8 tt -64.53 -37.81 81.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 121.018 0.437 . . . . 0.0 110.102 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.1 m95 -58.37 -29.53 66.07 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.866 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 -62.07 -31.71 72.17 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.009 -0.676 . . . . 0.0 109.634 179.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 9' ' ' LEU . 97.6 mt -70.87 -37.37 73.06 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.66 179.013 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.423 ' O ' HG23 ' A' ' 14' ' ' VAL . 3.2 mt -62.09 -46.51 88.75 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.449 HG23 ' N ' ' A' ' 12' ' ' ILE . 14.6 tt -67.18 -42.42 88.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.282 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.449 ' N ' HG23 ' A' ' 11' ' ' ILE . 82.6 mt -62.84 -43.33 98.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.275 179.054 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.82 -38.32 81.68 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.842 0.354 . . . . 0.0 110.307 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 10' ' ' LEU . 40.4 t -60.83 -43.1 94.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.944 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.463 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.4 mt -60.67 -44.04 96.2 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.533 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.751 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.8 t -57.67 -44.32 85.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.389 -179.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.0 t -62.71 -43.81 98.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.238 179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.406 HD23 ' HA ' ' A' ' 18' ' ' LEU . 35.3 mt -62.69 -48.12 80.67 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.729 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 41.7 mt -63.6 -42.05 98.27 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.467 -0.493 . . . . 0.0 110.757 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.9 m-85 -86.77 -12.07 49.18 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.509 179.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.18 160.21 0.01 OUTLIER Glycine 0 CA--C 1.543 1.806 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -72.82 -12.73 26.55 Favored 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 121.434 1.423 . . . . 0.0 114.544 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.52 -55.13 12.73 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 120.301 -0.559 . . . . 0.0 112.338 -179.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -68.82 -46.9 67.42 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.175 0.512 . . . . 0.0 110.584 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.455 HD23 ' O ' ' A' ' 25' ' ' LEU . 8.8 tt -63.49 -23.54 67.44 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.68 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.59 -51.57 35.54 Favored Glycine 0 C--N 1.333 0.381 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 9.5 t -65.69 -43.02 90.48 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.037 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.7 mt -64.34 -47.68 88.57 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.976 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -64.44 -50.94 56.52 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.009 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 13.1 t -59.69 -41.91 91.78 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 121.111 -0.236 . . . . 0.0 110.66 -179.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -63.44 -46.18 87.48 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 120.691 -0.403 . . . . 0.0 110.381 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 69.0 mt -79.51 -20.98 45.9 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.669 179.322 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -82.17 0.65 88.53 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 111.558 -0.617 . . . . 0.0 111.558 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.72 -39.31 87.95 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.672 -179.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.5 m -69.54 -43.96 71.9 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.007 0.432 . . . . 0.0 110.793 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.5 mt -63.1 -41.36 92.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.012 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 66.6 tttm -56.44 -42.89 78.85 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.822 -0.627 . . . . 0.0 111.014 -178.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.22 -44.81 96.51 Favored Glycine 0 CA--C 1.522 0.489 0 C-N-CA 120.341 -0.933 . . . . 0.0 110.773 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -63.39 -44.88 93.42 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 178.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -60.04 -46.0 90.97 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.472 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -65.39 -53.29 45.39 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.971 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -59.8 -31.58 69.83 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 119.756 -0.778 . . . . 0.0 111.184 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.496 ' O ' ' N ' ' A' ' 45' ' ' ASP . 32.1 mmm -75.28 13.2 0.76 Allowed 'General case' 0 N--CA 1.453 -0.297 0 O-C-N 122.387 -0.196 . . . . 0.0 110.723 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 12.6 t 46.25 14.14 0.02 OUTLIER 'General case' 0 C--O 1.231 0.111 0 C-N-CA 120.962 -0.295 . . . . 0.0 110.724 179.309 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.496 ' N ' ' O ' ' A' ' 43' ' ' MET . 35.6 t70 -60.62 -43.24 97.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.45 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.48 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 37.0 t70 -51.91 178.87 0.01 OUTLIER 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.04 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.48 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 3.6 tp10 75.07 111.55 0.03 OUTLIER Pre-proline 0 CA--C 1.544 0.715 0 C-N-CA 120.918 -0.313 . . . . 0.0 110.874 179.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -72.45 155.54 55.17 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 120.874 1.049 . . . . 0.0 111.79 179.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 62.6 pttt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.254 179.239 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.56 -174.12 43.65 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.934 -0.867 . . . . 0.0 110.934 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 153.31 -8.81 0.49 Allowed Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 97.9 mt -63.16 -44.04 99.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.017 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 41.4 t -71.57 131.75 43.69 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.135 -0.484 . . . . 0.0 109.909 179.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 tt -66.0 -39.77 85.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.336 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.2 m95 -58.72 -28.42 65.82 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.182 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 68.9 tp60 -62.82 -31.36 72.34 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.259 -0.576 . . . . 0.0 109.717 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.7 mt -70.77 -38.34 73.43 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.163 -0.615 . . . . 0.0 110.414 178.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.418 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.2 mt -62.34 -48.18 80.96 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 111.933 0.346 . . . . 0.0 111.933 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.497 HG23 ' N ' ' A' ' 12' ' ' ILE . 20.0 tt -65.52 -42.95 94.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.158 -178.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.497 ' N ' HG23 ' A' ' 11' ' ' ILE . 77.8 mt -64.54 -43.4 96.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.518 179.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.69 -42.23 99.53 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.797 0.332 . . . . 0.0 110.458 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 10' ' ' LEU . 45.0 t -62.39 -45.54 98.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.202 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.485 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 74.3 mt -61.79 -45.46 98.65 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.644 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.806 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.1 t -58.48 -44.22 88.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.49 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.529 ' O ' ' N ' ' A' ' 21' ' ' GLY . 75.5 t -63.72 -43.33 97.99 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.202 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 18' ' ' LEU . 35.7 mt -63.13 -48.31 79.07 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.922 -178.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.8 mt -64.35 -41.89 96.51 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.757 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 21' ' ' GLY . 45.6 m-85 -88.35 -12.01 44.61 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.13 162.23 0.02 OUTLIER Glycine 0 CA--C 1.542 1.748 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -69.46 -25.52 29.89 Favored 'Trans proline' 0 N--CA 1.503 2.03 0 C-N-CA 121.505 1.47 . . . . 0.0 114.74 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.67 -50.59 62.41 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 120.324 -0.551 . . . . 0.0 112.366 -178.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 31.8 mmtp -67.07 -45.3 77.73 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.387 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.4 tt -61.46 -29.63 70.08 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.732 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.87 -50.98 49.82 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 28.2 m -66.49 -40.92 89.56 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.897 179.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.5 mt -64.72 -47.53 88.34 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.687 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.23 -51.21 56.72 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.1 m -60.59 -40.4 91.61 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.883 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -63.22 -45.25 92.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.848 0.356 . . . . 0.0 110.161 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.2 mt -79.1 -14.9 58.86 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.601 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -82.3 3.67 80.47 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -68.7 -39.2 80.6 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.887 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 39.0 t -65.6 -43.0 90.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.905 0.383 . . . . 0.0 110.584 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 87.6 mt -62.55 -41.38 91.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.751 -0.658 . . . . 0.0 109.987 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -56.37 -39.46 72.97 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.035 -178.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.02 -41.0 88.46 Favored Glycine 0 CA--C 1.52 0.389 0 C-N-CA 120.547 -0.835 . . . . 0.0 111.088 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -62.0 -47.13 86.15 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -63.91 -46.47 84.65 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.314 -0.555 . . . . 0.0 110.798 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -59.74 -50.31 74.31 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.759 -179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.69 -44.46 77.38 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.166 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 2.8 tpp -77.01 12.84 1.23 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 121.021 -0.271 . . . . 0.0 110.865 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 13.2 t -82.39 50.0 1.54 Allowed 'General case' 0 C--O 1.232 0.184 0 CA-C-O 120.692 0.282 . . . . 0.0 110.302 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -62.51 -40.97 98.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.566 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.472 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 38.9 t70 -150.1 178.83 8.59 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 120.921 -0.312 . . . . 0.0 110.177 179.487 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.472 ' H ' ' CG ' ' A' ' 46' ' ' ASP . 26.2 tt0 -162.83 87.67 1.34 Allowed Pre-proline 0 CA--C 1.537 0.463 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.36 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -76.5 158.37 36.3 Favored 'Trans proline' 0 N--CA 1.492 1.432 0 C-N-CA 121.215 1.277 . . . . 0.0 111.703 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 98.9 mttt . . . . . 0 C--N 1.333 -0.133 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.011 179.517 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . 0.541 ' SD ' ' CN ' ' A' ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -87.1 120.34 5.47 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -94.41 9.99 71.45 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 97.1 mt -63.19 -43.73 98.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.707 -0.397 . . . . 0.0 109.94 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.1 t -66.88 134.16 51.5 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.208 179.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.2 tt -65.34 -41.2 90.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.018 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.1 m95 -59.92 -31.32 69.72 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.178 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 41.7 mm-40 -64.99 -38.48 91.1 Favored 'General case' 0 C--O 1.22 -0.455 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.659 178.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 60.8 mt -71.68 -34.57 69.8 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.438 178.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -61.86 -47.13 86.4 Favored 'General case' 0 C--O 1.233 0.237 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 -177.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.468 HG23 ' N ' ' A' ' 12' ' ' ILE . 17.6 tt -65.21 -42.04 93.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.21 -178.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.468 ' N ' HG23 ' A' ' 11' ' ' ILE . 84.9 mt -64.15 -42.89 96.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.461 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.2 -40.7 94.93 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.784 0.326 . . . . 0.0 110.546 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.4 t -64.03 -43.27 97.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.071 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.471 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 77.8 mt -61.04 -43.93 97.2 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.744 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.8 t -57.39 -44.31 84.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.377 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.1 t -63.44 -43.56 98.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.119 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 35.9 mt -62.83 -48.63 78.25 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.75 -178.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.1 mt -63.9 -42.78 97.36 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.388 -0.525 . . . . 0.0 110.666 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.416 ' O ' ' O ' ' A' ' 21' ' ' GLY . 43.1 m-85 -86.19 -13.69 46.22 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.622 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 55.87 163.2 0.02 OUTLIER Glycine 0 CA--C 1.541 1.687 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -70.14 -19.62 34.07 Favored 'Trans proline' 0 N--CA 1.501 1.936 0 C-N-CA 121.584 1.523 . . . . 0.0 114.583 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -67.8 -52.23 39.46 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 120.292 -0.563 . . . . 0.0 112.283 -179.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -67.58 -44.1 78.98 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.209 0.528 . . . . 0.0 110.398 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.6 tt -60.97 -26.45 67.56 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.668 -179.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -64.95 -48.94 65.68 Favored Glycine 0 C--N 1.332 0.356 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.7 p -63.34 -40.51 97.49 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 121.004 -0.278 . . . . 0.0 110.932 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 95.2 mt -63.51 -47.67 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.712 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.59 -51.73 56.87 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.9 m -59.82 -35.24 74.29 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.988 -0.285 . . . . 0.0 110.618 -179.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -62.62 -44.07 97.21 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.804 -0.359 . . . . 0.0 110.101 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.2 mt -80.03 -16.35 55.29 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.516 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.04 -26.16 65.3 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.65 -38.24 90.34 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.691 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.1 m -70.69 -39.75 73.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.998 0.428 . . . . 0.0 110.706 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.2 mt -63.92 -41.62 93.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.963 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -56.28 -40.12 73.76 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.971 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.18 -43.8 88.54 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.541 -0.837 . . . . 0.0 111.023 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -62.16 -47.41 84.66 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 179.186 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -59.57 -45.7 91.09 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.339 -0.545 . . . . 0.0 110.692 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.3 tttp -62.62 -51.72 66.17 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.708 -179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -59.9 -45.24 93.18 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 119.602 -0.839 . . . . 0.0 111.36 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.435 ' O ' ' C ' ' A' ' 44' ' ' SER . 15.1 mtp -75.58 -8.8 57.68 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.769 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 43' ' ' MET . 19.8 m 36.14 75.07 0.06 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.527 0.203 . . . . 0.0 110.871 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.516 ' CG ' ' H ' ' A' ' 46' ' ' ASP . 12.3 p-10 -56.01 -66.3 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.315 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.516 ' H ' ' CG ' ' A' ' 45' ' ' ASP . 98.9 m-20 -140.98 139.78 34.27 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.194 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -156.27 147.66 16.83 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.724 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -65.28 -22.23 60.71 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 120.962 1.108 . . . . 0.0 111.826 179.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 61.6 pttt . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.276 -179.372 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . 0.455 ' O1 ' ' N ' ' A' ' 2' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.455 ' N ' ' O1 ' ' A' ' 1' ' ' FME . . . 81.24 11.61 83.26 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -61.42 -41.45 99.54 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 89.4 mt -112.24 127.47 69.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.858 0.361 . . . . 0.0 110.389 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.1 t -64.13 130.32 43.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.257 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.9 tt -65.34 -40.1 87.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.178 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 4.0 m95 -58.11 -29.44 65.5 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.904 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -63.01 -31.73 72.94 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 119.942 -0.703 . . . . 0.0 109.771 179.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.7 -39.1 73.66 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.383 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.435 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.5 mt -61.63 -48.22 81.86 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 111.825 0.306 . . . . 0.0 111.825 -179.025 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.458 HG23 ' N ' ' A' ' 12' ' ' ILE . 19.6 tt -66.0 -43.34 92.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.201 -0.599 . . . . 0.0 110.169 -179.304 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.458 ' N ' HG23 ' A' ' 11' ' ' ILE . 86.3 mt -64.17 -43.44 97.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.611 179.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.43 -40.53 94.8 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.599 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 10' ' ' LEU . 44.8 t -63.52 -45.32 98.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.784 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.473 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 79.9 mt -61.92 -44.62 99.13 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.671 0 C-N-CA 120.172 -0.611 . . . . 0.0 110.854 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 69.0 t -59.19 -44.59 92.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.401 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' A' ' 21' ' ' GLY . 79.6 t -63.44 -44.07 98.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.192 -179.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.2 mt -62.39 -48.57 79.14 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.576 -0.45 . . . . 0.0 112.156 -178.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.473 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 47.9 mt -63.91 -40.79 97.3 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.965 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -90.06 -13.73 35.29 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 121.202 -0.199 . . . . 0.0 111.51 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 57.33 163.36 0.04 OUTLIER Glycine 0 CA--C 1.532 1.124 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -68.79 -25.19 33.66 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.107 1.204 . . . . 0.0 114.443 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.0 tptp -67.19 -50.34 61.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.038 -0.665 . . . . 0.0 112.599 -178.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 72.6 mmtt -66.98 -45.44 77.65 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.343 -178.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 10.0 tt -62.35 -30.76 71.4 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.415 -179.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.85 -51.6 44.89 Favored Glycine 0 C--N 1.334 0.439 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.346 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 58.5 p -66.92 -41.54 86.89 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.01 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 94.6 mt -64.71 -47.91 86.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.921 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.86 -50.92 57.78 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 120.453 -0.879 . . . . 0.0 110.994 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p -60.71 -42.64 97.62 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.937 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -63.61 -45.42 90.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.891 0.377 . . . . 0.0 110.042 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.1 mt -79.26 -16.53 56.3 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.594 179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -87.18 5.65 84.75 Favored Glycine 0 CA--C 1.532 1.095 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.15 -38.19 78.63 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.122 0.461 . . . . 0.0 110.805 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 19.5 m -65.6 -43.51 89.43 Favored 'General case' 0 C--O 1.227 -0.123 0 CA-C-O 120.98 0.419 . . . . 0.0 110.7 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.3 mt -63.38 -41.92 94.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.116 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -57.6 -39.97 78.03 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.014 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.52 -41.14 90.7 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -61.3 -46.98 88.06 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.806 -0.358 . . . . 0.0 110.11 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -63.14 -45.48 91.71 Favored 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.703 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' ' O ' ' A' ' 44' ' ' SER . 4.4 tmtt? -61.94 -51.43 68.12 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.298 -178.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.72 -46.13 77.78 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 119.562 -0.855 . . . . 0.0 111.443 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 2.7 mpp? -79.25 13.66 1.79 Allowed 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 120.851 -0.34 . . . . 0.0 111.056 179.537 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 41' ' ' LYS . 40.0 t -137.97 144.86 41.37 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.458 ' OD1' ' N ' ' A' ' 45' ' ' ASP . 20.0 p-10 -88.32 -56.77 3.18 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 121.172 -0.211 . . . . 0.0 110.47 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 46.3 t0 -152.0 178.01 9.88 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 121.091 -0.244 . . . . 0.0 110.442 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -171.07 92.78 0.44 Allowed Pre-proline 0 CA--C 1.538 0.511 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.856 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -54.54 -34.91 84.22 Favored 'Trans proline' 0 N--CA 1.494 1.518 0 C-N-CA 120.799 0.999 . . . . 0.0 111.803 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 99.5 mttt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.763 -179.745 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.74 168.06 41.92 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 61.48 38.19 95.37 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 86.0 mt -47.66 -90.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.2 p -78.59 168.23 20.08 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.4 tt -63.17 -37.97 80.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.025 -179.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 3.6 m95 -57.96 -28.82 64.67 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.917 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -63.39 -31.91 73.2 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.0 mt -71.53 -37.71 71.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.142 -0.623 . . . . 0.0 110.464 179.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.474 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.6 mt -62.23 -47.48 84.23 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -178.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.487 HG23 ' N ' ' A' ' 12' ' ' ILE . 20.6 tt -67.19 -42.91 88.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.227 -179.334 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.487 ' N ' HG23 ' A' ' 11' ' ' ILE . 94.9 mt -63.68 -43.45 98.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.196 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.312 179.398 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -60.0 -38.64 83.2 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.891 0.377 . . . . 0.0 110.432 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 10' ' ' LEU . 42.8 t -61.76 -42.94 96.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.079 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.458 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.1 mt -60.77 -43.93 96.33 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.568 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.689 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 44.9 t -57.88 -43.98 85.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.286 -0.566 . . . . 0.0 110.387 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.496 ' O ' ' N ' ' A' ' 21' ' ' GLY . 54.6 t -63.18 -43.44 98.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.086 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 18' ' ' LEU . 34.0 mt -62.82 -48.54 78.65 Favored 'General case' 0 C--N 1.33 -0.26 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.751 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.458 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 39.3 mt -64.01 -42.06 97.26 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.667 -179.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' A' ' 21' ' ' GLY . 38.9 m-85 -85.47 -12.99 50.5 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 121.143 -0.223 . . . . 0.0 111.595 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.62 159.12 0.01 OUTLIER Glycine 0 CA--C 1.54 1.641 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -70.24 -22.5 29.78 Favored 'Trans proline' 0 N--CA 1.502 1.987 0 C-N-CA 121.465 1.444 . . . . 0.0 114.625 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 64.3 tttp -67.73 -52.33 38.79 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 120.449 -0.501 . . . . 0.0 112.256 -179.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 42.5 tttp -66.29 -44.61 83.03 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 120.447 -0.501 . . . . 0.0 110.443 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.7 tt -62.91 -25.69 68.44 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.653 -179.11 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.02 -50.38 58.05 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -65.85 -39.31 90.65 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.892 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.69 -47.76 89.7 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.134 0 C-N-CA 120.443 -0.503 . . . . 0.0 110.723 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -61.62 -50.77 62.9 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.0 m -59.69 -37.57 79.2 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 121.03 -0.268 . . . . 0.0 110.672 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -63.36 -44.91 93.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.933 0.397 . . . . 0.0 110.092 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.8 mt -81.22 -18.8 44.85 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.579 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -66.11 -10.72 53.04 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -67.9 -38.3 82.79 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.693 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.9 m -68.17 -39.54 82.52 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.096 0.474 . . . . 0.0 110.517 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 89.9 mt -63.95 -41.75 93.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.103 179.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -56.57 -41.97 77.81 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.231 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.92 -43.12 84.0 Favored Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.512 -0.851 . . . . 0.0 110.998 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -62.3 -46.68 87.67 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 38.5 ttmt -62.17 -45.35 93.81 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.433 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 30.9 ttpt -60.31 -51.62 68.75 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.724 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.18 -44.03 87.81 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 119.574 -0.851 . . . . 0.0 111.21 179.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 24.4 mtm -77.6 12.77 1.49 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 121.089 -0.244 . . . . 0.0 110.844 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 97.0 p -71.02 -17.74 62.61 Favored 'General case' 0 CA--C 1.526 0.049 0 CA-C-O 120.816 0.341 . . . . 0.0 110.557 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -62.21 -42.23 99.11 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.337 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -135.52 66.07 1.53 Allowed 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -168.88 90.63 0.6 Allowed Pre-proline 0 CA--C 1.538 0.481 0 C-N-CA 120.355 -0.538 . . . . 0.0 110.848 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -54.79 -38.93 91.82 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 120.917 1.078 . . . . 0.0 111.836 179.472 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 64.5 tttm . . . . . 0 C--N 1.332 -0.193 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.362 -179.89 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' FME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -69.1 149.12 48.69 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.07 35.17 0.72 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.949 -0.861 . . . . 0.0 110.949 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 86.0 mt -62.57 -43.98 98.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.9 t -96.41 123.28 40.0 Favored 'General case' 0 N--CA 1.463 0.195 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 tt -66.35 -40.4 86.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.278 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 3.3 m95 -58.39 -28.44 65.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.209 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 64.4 tp60 -63.68 -32.0 73.35 Favored 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 120.229 -0.588 . . . . 0.0 109.545 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 95.9 mt -70.89 -38.51 73.03 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 119.955 -0.698 . . . . 0.0 110.509 179.092 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.424 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.6 mt -62.12 -47.91 82.49 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -178.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.474 HG23 ' N ' ' A' ' 12' ' ' ILE . 19.7 tt -66.01 -42.69 92.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 C-N-CA 120.356 -0.538 . . . . 0.0 110.181 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.474 ' N ' HG23 ' A' ' 11' ' ' ILE . 83.2 mt -64.28 -43.78 97.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 120.671 -0.412 . . . . 0.0 110.598 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.23 -40.6 94.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.456 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 10' ' ' LEU . 43.0 t -62.47 -44.17 99.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.067 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.475 ' O ' ' HG ' ' A' ' 19' ' ' LEU . 75.6 mt -61.87 -44.96 99.59 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.612 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.936 -179.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 52.1 t -58.84 -44.22 90.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.473 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 21' ' ' GLY . 73.5 t -63.63 -43.38 98.13 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.71 -0.396 . . . . 0.0 111.249 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 18' ' ' LEU . 37.2 mt -63.16 -48.47 78.3 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.98 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 15' ' ' ILE . 42.3 mt -64.19 -41.02 97.26 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.872 -179.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 21' ' ' GLY . 44.7 m-85 -88.89 -12.28 42.21 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 111.609 0.226 . . . . 0.0 111.609 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 17' ' ' VAL . . . 56.42 161.26 0.02 OUTLIER Glycine 0 CA--C 1.54 1.63 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -70.25 -24.96 26.85 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 121.466 1.444 . . . . 0.0 114.718 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.76 -51.18 58.83 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 120.398 -0.521 . . . . 0.0 112.371 -178.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -67.28 -45.02 77.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.353 -0.539 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 9.0 tt -61.0 -29.1 69.5 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.716 -178.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -65.03 -50.72 56.36 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 78.1 p -65.26 -40.85 94.52 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.839 -0.344 . . . . 0.0 110.858 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.61 -47.57 90.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.668 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.529 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -63.05 -49.9 67.93 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.7 t -59.54 -43.1 93.59 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 121.039 -0.265 . . . . 0.0 110.585 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -62.03 -45.47 93.45 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.096 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.4 mt -79.18 -21.54 46.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.682 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -81.85 -0.24 89.18 Favored Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.565 -0.614 . . . . 0.0 111.565 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.97 -38.36 85.94 Favored 'General case' 0 CA--C 1.527 0.072 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.857 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 38.3 t -65.21 -40.51 94.24 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.091 0.472 . . . . 0.0 110.54 179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 90.9 mt -61.81 -41.2 89.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.995 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -57.37 -41.32 79.92 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.057 -179.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.01 -38.87 94.5 Favored Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.592 -0.813 . . . . 0.0 111.106 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.456 ' O ' ' CE ' ' A' ' 43' ' ' MET . 5.5 m-85 -62.13 -47.67 83.56 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -64.98 -46.5 81.19 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.771 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -58.88 -49.02 79.33 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 120.51 -0.476 . . . . 0.0 110.942 -179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.96 -46.79 75.06 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 119.49 -0.884 . . . . 0.0 111.144 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.456 ' CE ' ' O ' ' A' ' 39' ' ' PHE . 3.4 mpp? -78.23 12.94 1.66 Allowed 'General case' 0 CA--C 1.534 0.342 0 O-C-N 122.209 -0.307 . . . . 0.0 110.787 179.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 22.7 t -144.32 43.05 1.41 Allowed 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 120.756 0.312 . . . . 0.0 110.418 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -61.77 -44.69 96.39 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.777 -0.369 . . . . 0.0 110.451 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.522 ' CG ' ' H ' ' A' ' 47' ' ' GLU . 38.0 t70 -82.19 -178.2 6.93 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.54 ' N ' ' CD ' ' A' ' 47' ' ' GLU . 1.2 pm0 -153.32 79.6 5.48 Favored Pre-proline 0 CA--C 1.536 0.437 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.126 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -74.66 155.8 44.57 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 120.942 1.094 . . . . 0.0 112.011 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 65.1 tttm . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.218 179.395 . . . . . . . . 0 0 . 1 stop_ save_